


## EXHIBIT B

### U.S. PATENT APPLICATION SERIAL NO. 09/910,950 CLEAN VERSION OF CLAIMS PENDING AFTER ENTRY OF INSTANT AMENDMENT

5. A compound having the structure:



or a pharmaceutically acceptable salt thereof, wherein:

A is  $-(CH_2)_bCH=CH(CH_2)_c-$ ;

R<sub>1</sub> is aryl, heteroaryl or heterocycle fused to phenyl, each being optionally substituted with one to four substituents independently selected from R<sub>3</sub>;

R<sub>2</sub> is -R<sub>3</sub>,  $-(CH_2)_bC(=O)R_5$ ,  $-(CH_2)_bC(=O)OR_5$ ,  $-(CH_2)_bC(=O)NR_5R_6$ ,  $-(CH_2)_bC(=O)NR_5(CH_2)_cC(=O)R_6$ ,  $-(CH_2)_bNR_5C(=O)R_6$ ,  $-(CH_2)_bNR_5C(=O)NR_6R_7$ ,  $-(CH_2)_bNR_5R_6$ ,  $-(CH_2)_bOR_5$ ,  $-(CH_2)_bSO_dR_5$  or  $-(CH_2)_bSO_2NR_5R_6$ ;

b and c are the same or different and at each occurrence independently selected from 0, 1, 2, 3 or 4;


d is at each occurrence 0, 1 or 2;

R<sub>3</sub> is at each occurrence independently halogen, hydroxy, carboxy,  $-C(=O)OR_8$ ,  $-C(=O)R_8$ ,  $-C(O)NR_8R_9$ ,  $-C(=O)NR_8OR_9$ ,  $-SO_2NR_8R_9$ ,  $-NR_8SO_2R_9$ ,  $-CN$ ,  $-NO_2$ ,  $-NR_8R_9$ ,  $-NR_8C(=O)R_9$ ,  $-NR_8C(=O)(CH_2)_bOR_9$ ,  $-NR_8C(=O)(CH_2)_bR_9$ ,  $-O(CH_2)_bNR_8R_9$ ;

R<sub>5</sub>, R<sub>6</sub> and R<sub>7</sub> are the same or different and at each occurrence independently hydrogen, alkyl, aryl, arylalkyl, heterocycle or heterocyclealkyl, wherein each of R<sub>5</sub>, R<sub>6</sub> and R<sub>7</sub> are optionally substituted with one to four substituents independently selected from R<sub>3</sub>; and

R<sub>8</sub> and R<sub>9</sub> are the same or different and at each occurrence independently hydrogen, alkyl, aryl, arylalkyl, heterocycle, or heterocyclealkyl, or R<sub>8</sub> and R<sub>9</sub> taken together with the atom or atoms to which they are bonded form a heterocycle, wherein each of R<sub>8</sub>, R<sub>9</sub>, and R<sub>8</sub> and R<sub>9</sub> taken together to form a heterocycle are optionally substituted with one to four substituents independently selected from R<sub>3</sub>.

6. A compound having the structure:



or a pharmaceutically acceptable salt thereof, wherein:

A is  $-(CH_2)_bC \equiv C(CH_2)_c-$ ;

R<sub>1</sub> is aryl, heteroaryl or heterocycle fused to phenyl, each being optionally substituted with one to four substituents independently selected from R<sub>3</sub>;

R<sub>2</sub> is -R<sub>3</sub>, -R<sub>4</sub>,  $-(CH_2)_bC(=O)R_5$ ,  $-(CH_2)_bC(=O)OR_5$ ,  $-(CH_2)_bC(=O)NR_5R_6$ ,  $-(CH_2)_bC(=O)NR_5(CH_2)_cC(=O)R_6$ ,  $-(CH_2)_bNR_5C(=O)R_6$ ,  $-(CH_2)_bNR_5C(=O)NR_6R_7$ ,  $-(CH_2)_bNR_5R_6$ ,  $-(CH_2)_bOR_5$ ,  $-(CH_2)_bSO_dR_5$  or  $-(CH_2)_bSO_2NR_5R_6$ ;

b and c are the same or different and at each occurrence independently selected from 0, 1, 2, 3 or 4;

d-is-at-each-occurrence-0, 1 or 2;


R<sub>3</sub> is at each occurrence independently halogen, hydroxy, carboxy, alkyl, alkoxy, haloalkyl, acyloxy, thioalkyl, sulfinylalkyl, sulfonylalkyl, hydroxyalkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heterocycle, substituted heterocycle, heterocyclealkyl, substituted heterocyclealkyl,  $-C(=O)OR_8$ ,  $-C(=O)R_8$ ,  $-C(O)NR_8R_9$ ,  $-C(=O)NR_8OR_9$ ,  $-SO_2NR_8R_9$ ,  $-NR_8SO_2R_9$ ,  $-CN$ ,  $-NO_2$ ,  $-NR_8R_9$ ,  $-NR_8C(=O)R_9$ ,  $-NR_8C(=O)(CH_2)_bOR_9$ ,  $-NR_8C(=O)(CH_2)_bR_9$ ,  $-O(CH_2)_bNR_8R_9$ , or heterocycle fused to phenyl;

R<sub>4</sub> is alkyl, aryl, arylalkyl, heterocycle or heterocyclealkyl, each being optionally substituted with one to four substituents independently selected from R<sub>3</sub>, or R<sub>4</sub> is halogen or hydroxy;

R<sub>5</sub>, R<sub>6</sub> and R<sub>7</sub> are the same or different and at each occurrence independently hydrogen, alkyl, aryl, arylalkyl, heterocycle or heterocyclealkyl, wherein each of R<sub>5</sub>, R<sub>6</sub> and R<sub>7</sub> are optionally substituted with one to four substituents independently selected from R<sub>3</sub>; and

R<sub>8</sub> and R<sub>9</sub> are the same or different and at each occurrence independently hydrogen, alkyl, aryl, arylalkyl, heterocycle, or heterocyclealkyl, or R<sub>8</sub> and R<sub>9</sub> taken together with the atom or atoms to which they are bonded form a heterocycle, wherein each of R<sub>8</sub>, R<sub>9</sub>, and R<sub>8</sub> and R<sub>9</sub> taken together to form a heterocycle are optionally substituted with one to four substituents independently selected from R<sub>3</sub>.

10. A compound having the structure:



or a pharmaceutically acceptable salt thereof, wherein:

A is a direct bond,  $-(CH_2)_a-$ ,  $-(CH_2)_bCH=CH(CH_2)_c-$ , or  $-(CH_2)_bC \equiv C(CH_2)_c-$ ;

R<sub>1</sub> is aryl, heteroaryl or heterocycle fused to phenyl, each being optionally substituted with one to four substituents independently selected from

---

R<sub>3</sub>;

R<sub>2</sub> is  $-(CH_2)_bC(=O)R_5$ ;

a is 1, 2, 3, 4, 5 or 6;

b and c are the same or different and at each occurrence independently selected from 0, 1, 2, 3 or 4;


R<sub>3</sub> is at each occurrence independently halogen, hydroxy, carboxy, alkyl, alkoxy, haloalkyl, acyloxy, thioalkyl, sulfinylalkyl, sulfonylalkyl, hydroxyalkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heterocycle, substituted heterocycle, heterocyclealkyl, substituted heterocyclealkyl,  $-C(=O)OR_8$ ,  $-C(=O)R_8$ ,  $-C(O)NR_8R_9$ , -

$C(=O)NR_8OR_9$ ,  $-SO_2NR_8R_9$ ,  $-NR_8SO_2R_9$ ,  $-CN$ ,  $-NO_2$ ,  $-NR_8R_9$ ,  $-NR_8C(=O)R_9$ ,  $-NR_8C(=O)(CH_2)_bOR_9$ ,  $-NR_8C(=O)(CH_2)_bR_9$ ,  $-O(CH_2)_bNR_8R_9$ , or heterocycle fused to phenyl;

$R_5$ ,  $R_6$  and  $R_7$  are the same or different and at each occurrence independently alkyl, aryl, arylalkyl, heterocycle or heterocyclealkyl, wherein each of  $R_5$ ,  $R_6$  and  $R_7$  are optionally substituted with one to four substituents independently selected from  $R_3$ ; and

$R_8$  and  $R_9$  are the same or different and at each occurrence independently hydrogen, alkyl, aryl, arylalkyl, heterocycle, or heterocyclealkyl, or  $R_8$  and  $R_9$  taken together with the atom or atoms to which they are bonded form a heterocycle, wherein each of  $R_8$ ,  $R_9$ , and  $R_8$  and  $R_9$  taken together to form a heterocycle are optionally substituted with one to four substituents independently selected from  $R_3$ .

11. A compound having the structure:



or a pharmaceutically acceptable salt thereof, wherein:

A is a direct bond,  $-(CH_2)_a-$ ,  $-(CH_2)_bCH=CH(CH_2)_c-$ , or  $-(CH_2)_bC\equiv C(CH_2)_c-$ ;

$R_1$  is aryl, heteroaryl or heterocycle fused to phenyl, each being optionally substituted with one to four substituents independently selected from  $R_3$ ;

$R_2$  is  $-(CH_2)_bC(=O)NR_5R_6$ ;

$a$  is 1, 2, 3, 4, 5 or 6;

$b$  and  $c$  are the same or different and at each occurrence independently selected from 0, 1, 2, 3 or 4;


$R_3$  is at each occurrence independently halogen, hydroxy, carboxy, alkyl, alkoxy, haloalkyl, acyloxy, thioalkyl, sulfinylalkyl, sulfonylalkyl, hydroxyalkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heterocycle, substituted heterocycle, heterocyclealkyl, substituted heterocyclealkyl,  $-C(=O)OR_8$ ,  $-C(=O)R_8$ ,  $-C(O)NR_8R_9$ ,

-C(=O)NR<sub>8</sub>OR<sub>9</sub>, -SO<sub>2</sub>NR<sub>8</sub>R<sub>9</sub>, -NR<sub>8</sub>SO<sub>2</sub>R<sub>9</sub>, -CN, -NO<sub>2</sub>, -NR<sub>8</sub>R<sub>9</sub>,  
 -NR<sub>8</sub>C(=O)R<sub>9</sub>, -NR<sub>8</sub>C(=O)(CH<sub>2</sub>)<sub>b</sub>OR<sub>9</sub>, -NR<sub>8</sub>C(=O)(CH<sub>2</sub>)<sub>b</sub>R<sub>9</sub>,  
 -O(CH<sub>2</sub>)<sub>b</sub>NR<sub>8</sub>R<sub>9</sub>, or heterocycle fused to phenyl;

R<sub>5</sub>, R<sub>6</sub> and R<sub>7</sub> are the same or different and at each occurrence independently hydrogen, alkyl, aryl, arylalkyl, heterocycle or heterocyclealkyl, wherein each of R<sub>5</sub>, R<sub>6</sub> and R<sub>7</sub> are optionally substituted with one to four substituents independently selected from R<sub>3</sub>; and

R<sub>8</sub> and R<sub>9</sub> are the same or different and at each occurrence independently hydrogen, alkyl, aryl, arylalkyl, heterocycle, or heterocyclealkyl, or R<sub>8</sub> and R<sub>9</sub> taken together with the atom or atoms to which they are bonded form a heterocycle, wherein each of R<sub>8</sub>, R<sub>9</sub>, and R<sub>8</sub> and R<sub>9</sub> taken together to form a heterocycle are optionally substituted with one to four substituents independently selected from R<sub>3</sub>.

12. A compound having the structure:



or a pharmaceutically acceptable salt thereof, wherein:

A is a direct bond, -(CH<sub>2</sub>)<sub>a</sub>-, -(CH<sub>2</sub>)<sub>b</sub>CH=CH(CH<sub>2</sub>)<sub>c</sub>-, or -(CH<sub>2</sub>)<sub>b</sub>C≡C(CH<sub>2</sub>)<sub>c</sub>-  
 ;

R<sub>1</sub> is aryl, heteroaryl or heterocycle fused to phenyl, each being optionally substituted with one to four substituents independently selected from R<sub>3</sub>;

R<sub>2</sub> is -(CH<sub>2</sub>)<sub>b</sub>NR<sub>5</sub>C(=O)R<sub>6</sub>;

a is 1, 2, 3, 4, 5 or 6;

b and c are the same or different and at each occurrence independently selected from 0, 1, 2, 3 or 4;


R<sub>3</sub> is at each occurrence independently halogen, hydroxy, carboxy, alkyl, alkoxy, haloalkyl, acyloxy, thioalkyl, sulfinylalkyl, sulfonylalkyl, hydroxyalkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heterocycle, substituted heterocycle, heterocyclealkyl, substituted

heterocyclealkyl,  $-\text{C}(=\text{O})\text{OR}_8$ ,  $-\text{C}(=\text{O})\text{R}_8$ ,  $-\text{C}(\text{O})\text{NR}_8\text{R}_9$ ,  
 $-\text{C}(=\text{O})\text{NR}_8\text{OR}_9$ ,  $-\text{SO}_2\text{NR}_8\text{R}_9$ ,  $-\text{NR}_8\text{SO}_2\text{R}_9$ ,  $-\text{CN}$ ,  $-\text{NO}_2$ ,  $-\text{NR}_8\text{R}_9$ ,  
 $-\text{NR}_8\text{C}(=\text{O})\text{R}_9$ ,  $-\text{NR}_8\text{C}(=\text{O})(\text{CH}_2)_b\text{OR}_9$ ,  $-\text{NR}_8\text{C}(=\text{O})(\text{CH}_2)_b\text{R}_9$ ,  
 $-\text{O}(\text{CH}_2)_b\text{NR}_8\text{R}_9$ , or heterocycle fused to phenyl;

$\text{R}_5$ ,  $\text{R}_6$  and  $\text{R}_7$  are the same or different and at each occurrence independently hydrogen, alkyl, aryl, arylalkyl, heterocycle or heterocyclealkyl, wherein each of  $\text{R}_5$ ,  $\text{R}_6$  and  $\text{R}_7$  are optionally substituted with one to four substituents independently selected from  $\text{R}_3$ ; and

$\text{R}_8$  and  $\text{R}_9$  are the same or different and at each occurrence independently hydrogen, alkyl, aryl, arylalkyl, heterocycle, or heterocyclealkyl, or  $\text{R}_8$  and  $\text{R}_9$  taken together with the atom or atoms to which they are bonded form a heterocycle, wherein each of  $\text{R}_8$ ,  $\text{R}_9$ , and  $\text{R}_8$  and  $\text{R}_9$  taken together to form a heterocycle are optionally substituted with one to four substituents independently selected from  $\text{R}_3$ .

13. A compound having the structure:



or a pharmaceutically acceptable salt thereof, wherein:

A is a direct bond,  $-(\text{CH}_2)_a-$ ,  $-(\text{CH}_2)_b\text{CH}=\text{CH}(\text{CH}_2)_c-$ , or  $-(\text{CH}_2)_b\text{C}\equiv\text{C}(\text{CH}_2)_c-$ ;

$\text{R}_1$  is aryl, heteroaryl or heterocycle fused to phenyl, each being optionally substituted with one to four substituents independently selected from  $\text{R}_3$ ;

$\text{R}_2$  is  $-(\text{CH}_2)_b\text{NR}_5\text{R}_6$ ;

$a$  is 1, 2, 3, 4, 5 or 6;

$b$  and  $c$  are the same or different and at each occurrence independently selected from 0, 1, 2, 3 or 4;


$\text{R}_3$  is at each occurrence independently halogen, hydroxy, carboxy, alkyl, alkoxy, haloalkyl, acyloxy, thioalkyl, sulfinylalkyl, sulfonylalkyl, hydroxyalkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heterocycle, heterocyclealkyl, substituted heterocyclealkyl, -

$C(=O)OR_8$ ,  $-C(=O)R_8$ ,  $-C(O)NR_8R_9$ ,  $-C(=O)NR_8OR_9$ ,  $-SO_2NR_8R_9$ ,  $-NR_8SO_2R_9$ ,  $-CN$ ,  $-NO_2$ ,  $-NR_8R_9$ ,  $-NR_8C(=O)R_9$ ,  $-NR_8C(=O)(CH_2)_bOR_9$ ,  $-NR_8C(=O)(CH_2)_bR_9$ ,  $-O(CH_2)_bNR_8R_9$ , or heterocycle fused to phenyl;

$R_5$ ,  $R_6$  and  $R_7$  are the same or different and at each occurrence independently hydrogen, alkyl, aryl, arylalkyl, heterocycle or heterocyclealkyl, wherein each of  $R_5$ ,  $R_6$  and  $R_7$  are optionally substituted with one to four substituents independently selected from  $R_3$ ; and

$R_8$  and  $R_9$  are the same or different and at each occurrence independently hydrogen, alkyl, aryl, arylalkyl, heterocycle, or heterocyclealkyl, or  $R_8$  and  $R_9$  taken together with the atom or atoms to which they are bonded form a heterocycle, wherein each of  $R_8$ ,  $R_9$ , and  $R_8$  and  $R_9$  taken together to form a heterocycle are optionally substituted with one to four substituents independently selected from  $R_3$ .

18. A compound having the structure:



or a pharmaceutically acceptable salt thereof, wherein:

A is a direct bond,  $-(CH_2)_a-$ ,  $-(CH_2)_bCH=CH(CH_2)_c-$ , or  $-(CH_2)_bC\equiv C(CH_2)_c-$ ;

$R_1$  is aryl, heteroaryl or heterocycle fused to phenyl, each being optionally substituted with one to four substituents independently selected from  $R_3$ ;

$R_2$  is  $R_4$ ;

$a$  is 1, 2, 3, 4, 5 or 6;

$b$  and  $c$  are the same or different and at each occurrence independently selected from 0, 1, 2, 3 or 4;

$R_3$  is at each occurrence independently halogen, hydroxy, carboxy, alkyl, alkoxy, haloalkyl, acyloxy, thioalkyl, sulfinylalkyl, sulfonylalkyl, hydroxyalkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heterocycle, substituted heterocycle, heterocyclealkyl, substituted

heterocyclealkyl,  $-C(=O)OR_8$ ,  $-C(=O)R_8$ ,  $-C(O)NR_8R_9$ ,  $-C(=O)NR_8OR_9$ ,  $-SO_2NR_8R_9$ ,  $-NR_8SO_2R_9$ ,  $-CN$ ,  $-NO_2$ ,  $-NR_8R_9$ ,  $-NR_8C(=O)R_9$ ,  $-NR_8C(=O)(CH_2)_bOR_9$ ,  $-NR_8C(=O)(CH_2)_bR_9$ ,  $-O(CH_2)_bNR_8R_9$ , or heterocycle fused to phenyl;


$R_4$  is 3-triazolyl, optionally substituted at its 5-position with:

- (a) a  $C_1$ - $C_4$  straight or branched chain alkyl group optionally substituted with a hydroxyl, methylamino, dimethylamino or 1-pyrrolidinyl group; or
- (b) a 2-pyrrolidinyl group;

$R_5$ ,  $R_6$  and  $R_7$  are the same or different and at each occurrence independently hydrogen, alkyl, aryl, arylalkyl, heterocycle or heterocyclealkyl, wherein each of  $R_5$ ,  $R_6$  and  $R_7$  are optionally substituted with one to four substituents independently selected from  $R_3$ ; and

$R_8$  and  $R_9$  are the same or different and at each occurrence independently hydrogen, alkyl, aryl, arylalkyl, heterocycle, or heterocyclealkyl, or  $R_8$  and  $R_9$  taken together with the atom or atoms to which they are bonded form a heterocycle, wherein each of  $R_8$ ,  $R_9$ , and  $R_8$  and  $R_9$  taken together to form a heterocycle are optionally substituted with one to four substituents independently selected from  $R_3$ .

19. A compound having the structure:



or a pharmaceutically acceptable salt thereof, wherein:

A is a direct bond,  $-(CH_2)_a-$ ,  $-(CH_2)_bCH=CH(CH_2)_c-$ , or  $-(CH_2)_bC\equiv C(CH_2)_c-$ ;

$R_1$  is aryl, heteroaryl or heterocycle fused to phenyl, each being optionally substituted with one to four substituents independently selected from  $R_3$ ;

$R_2$  is  $R_4$ ;

a is 1, 2, 3, 4, 5 or 6;



*b* and *c* are the same or different and at each occurrence independently selected from 0, 1, 2, 3 or 4;


$R_3$  is at each occurrence independently halogen, hydroxy, carboxy, alkyl, alkoxy, haloalkyl, acyloxy, thioalkyl, sulfinylalkyl, sulfonylalkyl, hydroxyalkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heterocycle, substituted heterocycle, heterocyclealkyl, substituted heterocyclealkyl,  $-C(=O)OR_8$ ,  $-C(=O)R_8$ ,  $-C(O)NR_8R_9$ ,  $-C(=O)NR_8OR_9$ ,  $-SO_2NR_8R_9$ ,  $-NR_8SO_2R_9$ ,  $-CN$ ,  $-NO_2$ ,  $-NR_8R_9$ ,  $-NR_8C(=O)R_9$ ,  $-NR_8C(=O)(CH_2)_bOR_9$ ,  $-NR_8C(=O)(CH_2)_bR_9$ ,  $-O(CH_2)_bNR_8R_9$ , or heterocycle fused to phenyl;

$R_4$  is tetrazole;

$R_5$ ,  $R_6$  and  $R_7$  are the same or different and at each occurrence independently hydrogen, alkyl, aryl, arylalkyl, heterocycle or heterocyclealkyl, wherein each of  $R_5$ ,  $R_6$  and  $R_7$  are optionally substituted with one to four substituents independently selected from  $R_3$ ; and

$R_8$  and  $R_9$  are the same or different and at each occurrence independently hydrogen, alkyl, aryl, arylalkyl, heterocycle, or heterocyclealkyl, or  $R_8$  and  $R_9$  taken together with the atom or atoms to which they are bonded form a heterocycle, wherein each of  $R_8$ ,  $R_9$ , and  $R_8$  and  $R_9$  taken together to form a heterocycle are optionally substituted with one to four substituents independently selected from  $R_3$ .

20. A compound having the structure:



or a pharmaceutically acceptable salt thereof, wherein:

$A$  is a direct bond,  $-(CH_2)_a-$ ,  $-(CH_2)_bCH=CH(CH_2)_c-$ , or  $-(CH_2)_bC\equiv C(CH_2)_c-$ ;

$R_1$  is aryl, heteroaryl or heterocycle fused to phenyl, each being optionally substituted with one to four substituents independently selected from  $R_3$ ;

$R_2$  is  $R_4$ ;

$a$  is 1, 2, 3, 4, 5 or 6;

$b$  and  $c$  are the same or different and at each occurrence independently selected from 0, 1, 2, 3 or 4;


$R_3$  is at each occurrence independently halogen, hydroxy, carboxy, alkyl, alkoxy, haloalkyl, acyloxy, thioalkyl, sulfinylalkyl, sulfonylalkyl, hydroxyalkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heterocycle, substituted heterocycle, heterocyclealkyl, substituted heterocyclealkyl,  $-C(=O)OR_8$ ,  $-C(=O)R_8$ ,  $-C(O)NR_8R_9$ ,  $-C(=O)NR_8OR_9$ ,  $-SO_2NR_8R_9$ ,  $-NR_8SO_2R_9$ ,  $-CN$ ,  $-NO_2$ ,  $-NR_8R_9$ ,  $-NR_8C(=O)R_9$ ,  $-NR_8C(=O)(CH_2)_bOR_9$ ,  $-NR_8C(=O)(CH_2)_bR_9$ ,  $-O(CH_2)_bNR_8R_9$ , or heterocycle fused to phenyl;

$R_4$  is imidazole;

$R_5$ ,  $R_6$  and  $R_7$  are the same or different and at each occurrence independently hydrogen, alkyl, aryl, arylalkyl, heterocycle or heterocyclealkyl, wherein each of  $R_5$ ,  $R_6$  and  $R_7$  are optionally substituted with one to four substituents independently selected from  $R_3$ ; and

$R_8$  and  $R_9$  are the same or different and at each occurrence independently hydrogen, alkyl, aryl, arylalkyl, heterocycle, or heterocyclealkyl, or  $R_8$  and  $R_9$  taken together with the atom or atoms to which they are bonded form a heterocycle, wherein each of  $R_8$ ,  $R_9$ , and  $R_8$  and  $R_9$  taken together to form a heterocycle are optionally substituted with one to four substituents independently selected from  $R_3$ .

22. A method for treating a condition responsive to JNK inhibition, comprising administering to a patient in need thereof an effective amount of a compound having the structure:



or a pharmaceutically acceptable salt thereof,

wherein:

A is a direct bond,  $-(CH_2)_a-$ ,  $-(CH_2)_bCH=CH(CH_2)_c-$ , or  $-(CH_2)_bC\equiv C(CH_2)_c-$ ;

R<sub>1</sub> is aryl, heteroaryl or heterocycle fused to phenyl, each being optionally substituted with one to four substituents independently selected from R<sub>3</sub>;

R<sub>2</sub> is -R<sub>3</sub>, -R<sub>4</sub>, -(CH<sub>2</sub>)<sub>b</sub>C(=O)R<sub>5</sub>, -(CH<sub>2</sub>)<sub>b</sub>C(=O)OR<sub>5</sub>, -(CH<sub>2</sub>)<sub>b</sub>C(=O)NR<sub>5</sub>R<sub>6</sub>, -(CH<sub>2</sub>)<sub>b</sub>C(=O)NR<sub>5</sub>(CH<sub>2</sub>)<sub>c</sub>C(=O)R<sub>6</sub>, -(CH<sub>2</sub>)<sub>b</sub>NR<sub>5</sub>C(=O)R<sub>6</sub>, -(CH<sub>2</sub>)<sub>b</sub>NR<sub>5</sub>C(=O)NR<sub>6</sub>R<sub>7</sub>, -(CH<sub>2</sub>)<sub>b</sub>NR<sub>5</sub>R<sub>6</sub>, -(CH<sub>2</sub>)<sub>b</sub>OR<sub>5</sub>, -(CH<sub>2</sub>)<sub>b</sub>SO<sub>d</sub>R<sub>5</sub> or -(CH<sub>2</sub>)<sub>b</sub>SO<sub>2</sub>NR<sub>5</sub>R<sub>6</sub>;

a is 1, 2, 3, 4, 5 or 6;

b and c are the same or different and at each occurrence independently selected from 0, 1, 2, 3 or 4;

d is at each occurrence 0, 1 or 2;

R<sub>3</sub> is at each occurrence independently halogen, hydroxy, carboxy, alkyl, alkoxy, haloalkyl, acyloxy, thioalkyl, sulfinylalkyl, sulfonylalkyl, hydroxyalkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heterocycle, substituted heterocycle, heterocyclealkyl, substituted heterocyclealkyl, -C(=O)OR<sub>8</sub>, -OC(=O)R<sub>8</sub>, -C(=O)NR<sub>8</sub>R<sub>9</sub>, -C(=O)NR<sub>8</sub>OR<sub>9</sub>, -SO<sub>2</sub>NR<sub>8</sub>R<sub>9</sub>, -NR<sub>8</sub>SO<sub>2</sub>R<sub>9</sub>, -CN, -NO<sub>2</sub>, -NR<sub>8</sub>R<sub>9</sub>, -NR<sub>8</sub>C(=O)R<sub>9</sub>, -NR<sub>8</sub>C(=O)(CH<sub>2</sub>)<sub>b</sub>OR<sub>9</sub>, -NR<sub>8</sub>C(=O)(CH<sub>2</sub>)<sub>b</sub>R<sub>9</sub>, -O(CH<sub>2</sub>)<sub>b</sub>NR<sub>8</sub>R<sub>9</sub>, or heterocycle fused to phenyl;

R<sub>4</sub> is alkyl, aryl, arylalkyl, heterocycle or heterocyclealkyl, each being optionally substituted with one to four substituents independently selected from R<sub>3</sub>, or R<sub>4</sub> is halogen or hydroxy;

R<sub>5</sub>, R<sub>6</sub> and R<sub>7</sub> are the same or different and at each occurrence independently hydrogen, alkyl, aryl, arylalkyl, heterocycle or heterocyclealkyl, wherein each of R<sub>5</sub>, R<sub>6</sub> and R<sub>7</sub> are optionally substituted with one to four substituents independently selected from R<sub>3</sub>; and

R<sub>8</sub> and R<sub>9</sub> are the same or different and at each occurrence independently hydrogen, alkyl, aryl, arylalkyl, heterocycle, or heterocyclealkyl, or R<sub>8</sub> and R<sub>9</sub> taken together with the atom or atoms to which they are bonded form a heterocycle, wherein each of R<sub>8</sub>, R<sub>9</sub>, and R<sub>8</sub> and R<sub>9</sub> taken together to form a heterocycle are optionally substituted with one to four substituents independently selected from R<sub>3</sub>.

23. The method of claim 22 wherein:


$R_2$  is  $-R_4$ ,  $-(CH_2)_bC(=O)R_5$ ,  $-(CH_2)_bC(=O)OR_5$ ,  $-(CH_2)_bC(=O)NR_5R_6$ ,  
 $-(CH_2)_bC(=O)NR_5(CH_2)_cC(=O)R_6$ ,  $-(CH_2)_bNR_5C(=O)R_6$ ,  
 $-(CH_2)_bNR_5C(=O)NR_6R_7$ ,  $-(CH_2)_bNR_5R_6$ ,  $-(CH_2)_bOR_5$ ,  $-(CH_2)_bSO_dR_5$  or  
 $-(CH_2)_bSO_2NR_5R_6$ .

24. The method of claim 22 wherein the condition is cancer.
25. The method of claim 22 wherein the condition is rheumatoid arthritis; rheumatoid spondylitis; osteoarthritis; gout; asthma, bronchitis; allergic rhinitis; chronic obstructive pulmonary disease; cystic fibrosis; inflammatory bowel disease; irritable bowel syndrome; mucous colitis; ulcerative colitis; Crohn's disease; Huntington's disease; gastritis; esophagitis; hepatitis; pancreatitis; nephritis; multiple sclerosis; endotoxin shock; lupus erythematosus; Type II diabetes; psoriasis; burn caused by exposure to fire, chemicals or radiation; eczema; dermatitis; skin graft; ischemia; ischemic conditions associated with surgery or traumatic injury; cachexia or angiogenic and proliferative diseases.
26. The method of claim 22 wherein the condition is atherosclerosis, restenosis following angioplasty, left ventricular hypertrophy, or myocardial infarction.
27. The method of claim 22 wherein the condition is stroke or ischemic damages of heart, lung, gut, kidney, liver, pancreas, spleen or brain.
28. The method of claim 22 wherein the condition is acute or chronic organ transplant rejection, preservation of the organ for transplantation, graft versus host disease or multiple organ failure.
29. The method of claim 22 wherein the condition is epilepsy, Alzheimer's disease, or Parkinson's disease.
30. The method of claim 22 wherein the condition is an immunological response to bacterial or viral infection.
31. The method of claim 22 wherein the condition is solid tumor or cancers of a variety of tissues such as colon, rectum, prostate, liver, lung, bronchus, pancreas, brain, head, neck, stomach, skin, kidney, cervix, blood, larynx, esophagus, mouth, pharynx, urinary bladder, ovary or uterine.

32. The method of claim 22 wherein A is a direct bond.
33. The method of claim 22 wherein A is  $-(CH_2)_a-$ .
34. The method of claim 22 wherein A is  $-(CH_2)_bCH=CH(CH_2)_c-$ .
35. The method of claim 22 wherein A is  $-(CH_2)_bC\equiv C(CH_2)_c-$ .
36. The method of claim 22 wherein  $R_1$  is aryl optionally substituted with one to four substituents independently selected from  $R_3$ .
37. The method of claim 22 wherein  $R_1$  is heteroaryl optionally substituted with one to four substituents independently selected from  $R_3$ .
38. The method of claim 22 wherein  $R_1$  is heterocycle fused to phenyl optionally substituted with one to four substituents independently selected from  $R_3$ .
39. The method of claim 22 wherein  $R_2$  is  $-(CH_2)_bC(=O)R_5$ .
40. The method of claim 22 wherein  $R_2$  is  $-(CH_2)_bC(=O)NR_5R_6$ .
41. The method of claim 22 wherein  $R_2$  is  $-(CH_2)NR_5C(=O)R_6$ .
42. The method of claim 22 wherein  $R_2$  is  $-(CH_2)_bNR_5R_6$ .
43. The method of claim 22 wherein  $R_2$  is  $R_4$ .
44. The method of claim 43 wherein  $R_4$  is substituted alkyl.
- 
45. The method of claim 43 wherein  $R_4$  is substituted arylalkyl.
46. The method of claim 43 wherein  $R_4$  is substituted heterocycle.
47. The method of claim 43 wherein  $R_4$  is 3-triazolyl, optionally substituted at its 5-position with:
- (a) a C1-C4 straight or branched chain alkyl group optionally substituted with a hydroxyl, methylamino, dimethylamino or 1-pyrrolidinyl group; or
  - (b) a 2-pyrrolidinyl group.
48. The method of claim 43 wherein  $R_4$  is tetrazole.

49. The method of claim 43 wherein R<sub>4</sub> is imidazole.

50. A method for treating or preventing rheumatoid arthritis; rheumatoid spondylitis; osteoarthritis; gout; asthma, bronchitis; allergic rhinitis; chronic obstructive pulmonary disease; cystic fibrosis; inflammatory bowel disease; irritable bowel syndrome; mucous colitis; ulcerative colitis; Crohn's disease; Huntington's disease; gastritis; esophagitis; hepatitis; pancreatitis; nephritis; multiple sclerosis; lupus erythematosus; Type II diabetes; atherosclerosis; restenosis following angioplasty; left ventricular hypertrophy; myocardial infarction; stroke; ischemic damages of heart, lung, gut, kidney, liver, pancreas, spleen and brain; acute or chronic organ transplant rejection; preservation of an organ for transplantation; graft versus host disease; endotoxin shock; multiple organ failure; psoriasis; burn caused by exposure to fire, chemicals, or radiation; eczema; dermatitis; skin graft; ischemia; ischemic conditions associated with surgery or traumatic injury; epilepsy; Alzheimer's disease; Parkinson's disease; immunological response to bacterial or viral infection; cachexia; angiogenic and proliferative diseases; solid tumor; and cancers of a variety of tissues such as colon, rectum, prostate, liver, lung, bronchus, pancreas, brain, head, neck, stomach, skin, kidney, cervix, blood, larynx, esophagus, mouth, pharynx, urinary bladder, ovary, or uterine comprising administering to a patient in need of such treatment or prevention an effective amount of a compound having the structure:



---

or a pharmaceutically acceptable salt thereof,

wherein:

A is a direct bond,  $-(CH_2)_a-$ ,  $-(CH_2)_bCH=CH(CH_2)_c-$ , or  $-(CH_2)_bC\equiv C(CH_2)_c-$ ;

R<sub>1</sub> is aryl, heteroaryl or heterocycle fused to phenyl, each being optionally substituted with one to four substituents independently selected from R<sub>3</sub>;

R<sub>2</sub> is -R<sub>3</sub>, -R<sub>4</sub>,  $-(CH_2)_bC(=O)R_5$ ,  $-(CH_2)_bC(=O)OR_5$ ,  $-(CH_2)_bC(=O)NR_5R_6$ ,  $-(CH_2)_bC(=O)NR_5(CH_2)_cC(=O)R_6$ ,  $-(CH_2)_bNR_5C(=O)R_6$ ,  $-(CH_2)_bNR_5C(=O)NR_6R_7$ ,  $-(CH_2)_bNR_5R_6$ ,  $-(CH_2)_bOR_5$ ,  $-(CH_2)_bSO_dR_5$  or  $-(CH_2)_bSO_2NR_5R_6$ ;

*a* is 1, 2, 3, 4, 5 or 6;

*b* and *c* are the same or different and at each occurrence independently selected from 0, 1, 2, 3 or 4;

*d* is at each occurrence 0, 1 or 2;

R<sub>3</sub> is at each occurrence independently halogen, hydroxy, carboxy, alkyl, alkoxy, haloalkyl, acyloxy, thioalkyl, sulfinylalkyl, sulfonylalkyl, hydroxyalkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heterocycle, substituted heterocycle, heterocyclealkyl, substituted heterocyclealkyl, -C(=O)OR<sub>8</sub>, -OC(=O)R<sub>8</sub>, -C(=O)NR<sub>8</sub>R<sub>9</sub>, -C(=O)NR<sub>8</sub>OR<sub>9</sub>, -SO<sub>2</sub>NR<sub>8</sub>R<sub>9</sub>, -NR<sub>8</sub>SO<sub>2</sub>R<sub>9</sub>, -CN, -NO<sub>2</sub>, -NR<sub>8</sub>R<sub>9</sub>, -NR<sub>8</sub>C(=O)R<sub>9</sub>, -NR<sub>8</sub>C(=O)(CH<sub>2</sub>)<sub>b</sub>OR<sub>9</sub>, -NR<sub>8</sub>C(=O)(CH<sub>2</sub>)<sub>b</sub>R<sub>9</sub>, -O(CH<sub>2</sub>)<sub>b</sub>NR<sub>8</sub>R<sub>9</sub>, or heterocycle fused to phenyl;

R<sub>4</sub> is alkyl, aryl, arylalkyl, heterocycle or heterocyclealkyl, each being optionally substituted with one to four substituents independently selected from R<sub>3</sub>, or R<sub>4</sub> is halogen or hydroxy;

R<sub>5</sub>, R<sub>6</sub> and R<sub>7</sub> are the same or different and at each occurrence independently hydrogen, alkyl, aryl, arylalkyl, heterocycle or heterocyclealkyl, wherein each of R<sub>5</sub>, R<sub>6</sub> and R<sub>7</sub> are optionally substituted with one to four substituents independently selected from R<sub>3</sub>; and

R<sub>8</sub> and R<sub>9</sub> are the same or different and at each occurrence independently hydrogen, alkyl, aryl, arylalkyl, heterocycle, or heterocyclealkyl, or R<sub>8</sub> and R<sub>9</sub> taken together with the atom or atoms to which they are bonded form a heterocycle, wherein each of R<sub>8</sub>, R<sub>9</sub>, and R<sub>8</sub> and R<sub>9</sub> taken together to form a heterocycle are optionally substituted with one to four substituents independently selected from R<sub>3</sub>.

51. The method of claim 50 wherein:


R<sub>2</sub> is -R<sub>4</sub>, -(CH<sub>2</sub>)<sub>b</sub>C(=O)R<sub>5</sub>, -(CH<sub>2</sub>)<sub>b</sub>C(=O)OR<sub>5</sub>, -(CH<sub>2</sub>)<sub>b</sub>C(=O)NR<sub>5</sub>R<sub>6</sub>, -(CH<sub>2</sub>)<sub>b</sub>C(=O)NR<sub>5</sub>(CH<sub>2</sub>)<sub>c</sub>C(=O)R<sub>6</sub>, -(CH<sub>2</sub>)<sub>b</sub>NR<sub>5</sub>C(=O)R<sub>6</sub>, -(CH<sub>2</sub>)<sub>b</sub>NR<sub>5</sub>C(=O)NR<sub>6</sub>R<sub>7</sub>, -(CH<sub>2</sub>)<sub>b</sub>NR<sub>5</sub>R<sub>6</sub>, -(CH<sub>2</sub>)<sub>b</sub>OR<sub>5</sub>, -(CH<sub>2</sub>)<sub>b</sub>SO<sub>d</sub>R<sub>5</sub> or -(CH<sub>2</sub>)<sub>b</sub>SO<sub>2</sub>NR<sub>5</sub>R<sub>6</sub>.

52. The method of claim 50 wherein A is a direct bond.

53. The method of claim 50 wherein A is -(CH<sub>2</sub>)<sub>a</sub>-.

54. The method of claim 50 wherein A is  $-(\text{CH}_2)_b\text{CH}=\text{CH}(\text{CH}_2)_c-$ .
55. The method of claim 50 wherein A is  $-(\text{CH}_2)_b\text{C}\equiv\text{C}(\text{CH}_2)_c-$ .
56. The method of claim 50 wherein  $\text{R}_1$  is aryl optionally substituted with one to four substituents independently selected from  $\text{R}_3$ .
57. The method of claim 50 wherein  $\text{R}_1$  is heteroaryl optionally substituted with one to four substituents independently selected from  $\text{R}_3$ .
58. The method of claim 50 wherein  $\text{R}_1$  is heterocycle fused to phenyl optionally substituted with one to four substituents independently selected from  $\text{R}_3$ .
59. The method of claim 50 wherein  $\text{R}_2$  is  $-(\text{CH}_2)_b\text{C}(=\text{O})\text{R}_5$ .
60. The method of claim 50 wherein  $\text{R}_2$  is  $-(\text{CH}_2)_b\text{C}(=\text{O})\text{NR}_5\text{R}_6$ .
61. The method of claim 50 wherein  $\text{R}_2$  is  $-(\text{CH}_2)\text{NR}_5\text{C}(=\text{O})\text{R}_6$ .
62. The method of claim 50 wherein  $\text{R}_2$  is  $-(\text{CH}_2)_b\text{NR}_5\text{R}_6$ .
63. The method of claim 50 wherein  $\text{R}_2$  is  $\text{R}_4$ .
64. The method of claim 63 wherein  $\text{R}_4$  is substituted alkyl.
65. The method of claim 63 wherein  $\text{R}_4$  is substituted arylalkyl.
66. The method of claim 63 wherein  $\text{R}_4$  is substituted heterocycle.
- 
67. The method of claim 63 wherein  $\text{R}_4$  is 3-triazolyl, optionally substituted at its 5-position with:
- (a) a  $\text{C}_1$ - $\text{C}_4$  straight or branched chain alkyl group optionally substituted with a hydroxyl, methylamino, dimethylamino or 1-pyrrolidinyl group; or
  - (b) a 2-pyrrolidinyl group.
68. The method of claim 63 wherein  $\text{R}_4$  is tetrazole.
69. The method of claim 63 wherein  $\text{R}_4$  is imidazole.
71. A compound having the structure:





or a pharmaceutically acceptable salt thereof, wherein:

A is a direct bond,  $-(CH_2)_a-$ ,  $-(CH_2)_bCH=CH(CH_2)_c-$ , or  $-(CH_2)_bC\equiv C(CH_2)_c-$ ;

$R_1$  is aryl, heteroaryl or heterocycle fused to phenyl, each being optionally substituted with one to four substituents independently selected from  $R_3$ ;

$R_2$  is  $-(CH_2)_bC(=O)NR_5R_6$ ,  $-(CH_2)_bNR_5C(=O)R_6$ , 3-triazolyl or 5-tetrazolyl,  $a$  is 1, 2, 3, 4, 5 or 6;

$b$  is 0;

$c$  is at each occurrence 0, 1, 2, 3 or 4;

$R_3$  is at each occurrence independently halogen, hydroxy, carboxy, alkyl, alkoxy, haloalkyl, acyloxy, thioalkyl, sulfinylalkyl, sulfonylalkyl, hydroxyalkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heterocycle, substituted heterocycle, heterocyclealkyl, substituted heterocyclealkyl,  $-C(=O)OR_8$ ,  $-C(=O)R_8$ ,  $-C(O)NR_8R_9$ ,  $-C(=O)NR_8OR_9$ ,  $-SO_2NR_8R_9$ ,  $-NR_8SO_2R_9$ ,  $-CN$ ,  $-NO_2$ ,  $-NR_8R_9$ ,  $-NR_8C(=O)R_9$ ,  $-NR_8C(=O)(CH_2)_bOR_9$ ,  $-NR_8C(=O)(CH_2)_bR_9$ ,  $-O(CH_2)_bNR_8R_9$ , or heterocycle fused to phenyl;


$R_5$ ,  $R_6$  and  $R_7$  are the same or different and at each occurrence independently hydrogen, alkyl, aryl, arylalkyl, heterocycle or heterocyclealkyl,

---

wherein each of  $R_5$ ,  $R_6$  and  $R_7$  are optionally substituted with one to four substituents independently selected from  $R_3$ ; and

$R_8$  and  $R_9$  are the same or different and at each occurrence independently hydrogen, alkyl, aryl, arylalkyl, heterocycle, or heterocyclealkyl, or  $R_8$  and  $R_9$  taken together with the atom or atoms to which they are bonded form a heterocycle, wherein each of  $R_8$ ,  $R_9$ , and  $R_8$  and  $R_9$  taken together to form a heterocycle are optionally substituted with one to four substituents independently selected from  $R_3$ .

72. A compound having the structure:



or a pharmaceutically acceptable salt thereof, wherein:

A is a direct bond,  $-(CH_2)_a-$ ,  $-(CH_2)_bCH=CH(CH_2)_c-$ , or  $-(CH_2)_bC\equiv C(CH_2)_c-$ ;

$R_1$  is aryl, heteroaryl or heterocycle fused to phenyl, each being optionally substituted with one to four substituents independently selected from  $R_3$ ;

$R_2$  is 3-triazolyl or 5-tetrazolyl,

$a$  is 1, 2, 3, 4, 5 or 6;


$b$  and  $c$  are the same or different and at each occurrence independently selected from 0, 1, 2, 3 or 4;

$R_3$  is at each occurrence independently halogen, hydroxy, carboxy, alkyl, alkoxy, haloalkyl, acyloxy, thioalkyl, sulfinylalkyl, sulfonylalkyl, hydroxyalkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heterocycle, substituted heterocycle, heterocyclealkyl, substituted heterocyclealkyl,  $-C(=O)OR_8$ ,  $-C(=O)R_8$ ,  $-C(O)NR_8R_9$ ,  $-C(=O)NR_8OR_9$ ,  $-SO_2NR_8R_9$ ,  $-NR_8SO_2R_9$ ,  $-CN$ ,  $-NO_2$ ,  $-NR_8R_9$ ,  $-NR_8C(=O)R_9$ ,  $-NR_8C(=O)(CH_2)_bOR_9$ ,  $-NR_8C(=O)(CH_2)_bR_9$ ,  $-O(CH_2)_bNR_8R_9$ , or heterocycle fused to phenyl;

$R_5$ ,  $R_6$  and  $R_7$  are the same or different and at each occurrence independently hydrogen, alkyl, aryl, arylalkyl, heterocycle or heterocyclealkyl, wherein each of  $R_5$ ,  $R_6$  and  $R_7$  are optionally substituted with one to four substituents independently selected from  $R_3$ ; and

$R_8$  and  $R_9$  are the same or different and at each occurrence independently hydrogen, alkyl, aryl, arylalkyl, heterocycle, or heterocyclealkyl, or  $R_8$  and  $R_9$  taken together with the atom or atoms to which they are bonded form a heterocycle, wherein each of  $R_8$ ,  $R_9$ , and  $R_8$  and  $R_9$  taken together to form a heterocycle are optionally substituted with one to four substituents independently selected from  $R_3$ .

73. A compound having the structure:



or a pharmaceutically acceptable salt thereof, wherein:

-A-R<sub>1</sub> is phenyl, optionally substituted with one to four substituents

independently selected from halogen, alkoxy, -NR<sub>8</sub>C(=O)R<sub>9</sub>, -

C(=O)NR<sub>8</sub>R<sub>9</sub>,

and -O(CH<sub>2</sub>)<sub>b</sub>NR<sub>8</sub>R<sub>9</sub>, wherein *b* is 2 or 3;

R<sub>2</sub> is -(CH<sub>2</sub>)<sub>b</sub>C(=O)NR<sub>5</sub>R<sub>6</sub>, -(CH<sub>2</sub>)<sub>b</sub>NR<sub>5</sub>C(=O)R<sub>6</sub>, 3-triazolyl or 5-tetrazolyl,  
wherein *b* is 0;

*a* is 1, 2, 3, 4, 5 or 6;

*c* is at each occurrence 0, 1, 2, 3 or 4;

R<sub>3</sub> is at each occurrence independently halogen, hydroxy, carboxy, alkyl,

alkoxy, haloalkyl, acyloxy, thioalkyl, sulfinylalkyl, sulfonylalkyl,

hydroxyalkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl,

heterocycle, substituted heterocycle, heterocyclealkyl, substituted

heterocyclealkyl, -C(=O)OR<sub>8</sub>, -C(=O)R<sub>8</sub>, -C(O)NR<sub>8</sub>R<sub>9</sub>, -

C(=O)NR<sub>8</sub>OR<sub>9</sub>, -SO<sub>2</sub>NR<sub>8</sub>R<sub>9</sub>, -NR<sub>8</sub>SO<sub>2</sub>R<sub>9</sub>, -CN, -NO<sub>2</sub>, -NR<sub>8</sub>R<sub>9</sub>,

-NR<sub>8</sub>C(=O)R<sub>9</sub>, -NR<sub>8</sub>C(=O)(CH<sub>2</sub>)<sub>b</sub>OR<sub>9</sub>, -NR<sub>8</sub>C(=O)(CH<sub>2</sub>)<sub>b</sub>R<sub>9</sub>,

-O(CH<sub>2</sub>)<sub>b</sub>NR<sub>8</sub>R<sub>9</sub>, or heterocycle fused to phenyl;

R<sub>5</sub>, R<sub>6</sub> and R<sub>7</sub> are the same or different and at each occurrence independently

hydrogen, alkyl, aryl, arylalkyl, heterocycle or heterocyclealkyl,

wherein each of R<sub>5</sub>, R<sub>6</sub> and R<sub>7</sub> are optionally substituted with one to

four substituents independently selected from R<sub>3</sub>; and

R<sub>8</sub> and R<sub>9</sub> are the same or different and at each occurrence independently

hydrogen, alkyl, aryl, arylalkyl, heterocycle, or heterocyclealkyl, or


R<sub>8</sub> and R<sub>9</sub> taken together with the atom or atoms to which they are

bonded form a heterocycle, wherein each of R<sub>8</sub>, R<sub>9</sub>, and R<sub>8</sub> and R<sub>9</sub>

taken together to form a heterocycle are optionally substituted with

one to four substituents independently selected from R<sub>3</sub>.

74. A compound having the structure:



or a pharmaceutically acceptable salt thereof, wherein:

-A-R<sub>1</sub> is phenyl, optionally substituted with one to four substituents independently selected from halogen, alkoxy, -NR<sub>8</sub>C(=O)R<sub>9</sub>, -C(=O)NR<sub>8</sub>R<sub>9</sub>, and -O(CH<sub>2</sub>)<sub>b</sub>NR<sub>8</sub>R<sub>9</sub>;

R<sub>2</sub> is 3-triazolyl or 5-tetrazolyl;

a is 1, 2, 3, 4, 5 or 6;

b is 2 or 3;

c is at each occurrence 0, 1, 2, 3 or 4;

R<sub>3</sub> is at each occurrence independently halogen, hydroxy, carboxy, alkyl, alkoxy, haloalkyl, acyloxy, thioalkyl, sulfinylalkyl, sulfonylalkyl, hydroxyalkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heterocycle, substituted heterocycle, heterocyclealkyl, substituted heterocyclealkyl, -C(=O)OR<sub>8</sub>, -C(=O)R<sub>8</sub>, -C(O)NR<sub>8</sub>R<sub>9</sub>, -C(=O)NR<sub>8</sub>OR<sub>9</sub>, -SO<sub>2</sub>NR<sub>8</sub>R<sub>9</sub>, -NR<sub>8</sub>SO<sub>2</sub>R<sub>9</sub>, -CN, -NO<sub>2</sub>, -NR<sub>8</sub>R<sub>9</sub>, -NR<sub>8</sub>C(=O)R<sub>9</sub>, -NR<sub>8</sub>C(=O)(CH<sub>2</sub>)<sub>b</sub>OR<sub>9</sub>, -NR<sub>8</sub>C(=O)(CH<sub>2</sub>)<sub>b</sub>R<sub>9</sub>, -O(CH<sub>2</sub>)<sub>b</sub>NR<sub>8</sub>R<sub>9</sub>, or heterocycle fused to phenyl;

R<sub>5</sub>, R<sub>6</sub> and R<sub>7</sub> are the same or different and at each occurrence independently hydrogen, alkyl, aryl, arylalkyl, heterocycle or heterocyclealkyl, wherein each of R<sub>5</sub>, R<sub>6</sub> and R<sub>7</sub> are optionally substituted with one to four substituents independently selected from R<sub>3</sub>; and

R<sub>8</sub> and R<sub>9</sub> are the same or different and at each occurrence independently hydrogen, alkyl, aryl, arylalkyl, heterocycle, or heterocyclealkyl, or R<sub>8</sub> and R<sub>9</sub> taken together with the atom or atoms to which they are bonded form a heterocycle, wherein each of R<sub>8</sub>, R<sub>9</sub>, and R<sub>8</sub> and R<sub>9</sub> taken together to form a heterocycle are optionally substituted with one to four substituents independently selected from R<sub>3</sub>.

75. The method of claim 22, wherein -A-R<sub>1</sub> is phenyl, optionally substituted with one to four substituents independently selected from halogen, alkoxy, -NR<sub>8</sub>C(=O)R<sub>9</sub>, -C(=O)NR<sub>8</sub>R<sub>9</sub>, and -O(CH<sub>2</sub>)<sub>b</sub>NR<sub>8</sub>R<sub>9</sub>, wherein *b* is 2 or 3.

76. The method of claim 22, wherein R<sub>2</sub> is -(CH<sub>2</sub>)<sub>b</sub>C(=O)NR<sub>5</sub>R<sub>6</sub>, -(CH<sub>2</sub>)<sub>b</sub>NR<sub>5</sub>C(=O)R<sub>6</sub>, 3-triazolyl or 5-tetrazolyl, wherein *b* is 0.

77. The method of claim 22, wherein R<sub>2</sub> is 3-triazolyl or 5-tetrazolyl.

78. The method of claim 22, wherein:

(a) -A-R<sub>1</sub> is phenyl, optionally substituted with one to four substituents independently selected from halogen, alkoxy, -NR<sub>8</sub>C(=O)R<sub>9</sub>, -C(=O)NR<sub>8</sub>R<sub>9</sub>, and -O(CH<sub>2</sub>)<sub>b</sub>NR<sub>8</sub>R<sub>9</sub>, wherein *b* is 2 or 3; and

(b) R<sub>2</sub> is -(CH<sub>2</sub>)<sub>b</sub>C(=O)NR<sub>5</sub>R<sub>6</sub>, -(CH<sub>2</sub>)<sub>b</sub>NR<sub>5</sub>C(=O)R<sub>6</sub>, 3-triazolyl or 5-tetrazolyl, wherein *b* is 0.

79. The method of claim 22, wherein

(a) -A-R<sub>1</sub> is phenyl, optionally substituted with one to four substituents independently selected from halogen, alkoxy, -NR<sub>8</sub>C(=O)R<sub>9</sub>, -C(=O)NR<sub>8</sub>R<sub>9</sub>, and -O(CH<sub>2</sub>)<sub>b</sub>NR<sub>8</sub>R<sub>9</sub>, wherein *b* is 2 or 3; and

(b) R<sub>2</sub> is 3-triazolyl or 5-tetrazolyl.

80. The method of claim 50, wherein -A-R<sub>1</sub> is phenyl, optionally substituted with one to four substituents independently selected from halogen, alkoxy, -NR<sub>8</sub>C(=O)R<sub>9</sub>, -C(=O)NR<sub>8</sub>R<sub>9</sub>, and -O(CH<sub>2</sub>)<sub>b</sub>NR<sub>8</sub>R<sub>9</sub>, wherein *b* is 2 or 3.

---

81. The method of claim 50, wherein R<sub>2</sub> is -(CH<sub>2</sub>)<sub>b</sub>C(=O)NR<sub>5</sub>R<sub>6</sub>, -(CH<sub>2</sub>)<sub>b</sub>NR<sub>5</sub>C(=O)R<sub>6</sub>, 3-triazolyl or 5-tetrazolyl, wherein *b* is 0.

82. The method of claim 50, wherein R<sub>2</sub> is 3-triazolyl or 5-tetrazolyl.

83. The method of claim 50, wherein:


(a) -A-R<sub>1</sub> is phenyl, optionally substituted with one to four substituents independently selected from halogen, alkoxy, -NR<sub>8</sub>C(=O)R<sub>9</sub>, -C(=O)NR<sub>8</sub>R<sub>9</sub>, and -O(CH<sub>2</sub>)<sub>b</sub>NR<sub>8</sub>R<sub>9</sub>, wherein *b* is 2 or 3; and

(b) R<sub>2</sub> is -(CH<sub>2</sub>)<sub>b</sub>C(=O)NR<sub>5</sub>R<sub>6</sub>, -(CH<sub>2</sub>)<sub>b</sub>NR<sub>5</sub>C(=O)R<sub>6</sub>, 3-triazolyl or 5-tetrazolyl, wherein *b* is 0.

84. The method of claim 50, wherein:

- (a)  $-A-R_1$  is phenyl, optionally substituted with one to four substituents independently selected from halogen, alkoxy,  $-NR_8C(=O)R_9$ ,  $-C(=O)NR_8R_9$ , and  $-O(CH_2)_bNR_8R_9$ , wherein  $b$  is 2 or 3; and
- (b)  $R_2$  is 3-triazolyl or 5-tetrazolyl.

85. A compound having the structure:



or a pharmaceutically acceptable salt thereof, wherein:

$A$  is a direct bond,  $-(CH_2)_a-$ ,  $-(CH_2)_bCH=CH(CH_2)_c-$ , or  $-(CH_2)_bC\equiv C(CH_2)_c-$ ;

$R_1$  is aryl, heteroaryl or heterocycle fused to phenyl, each being optionally substituted with one to four substituents independently selected from  $R_3$ ;

$R_2$  is  $R_4$ ;

$a$  is 1, 2, 3, 4, 5 or 6;

$b$  and  $c$  are the same or different and at each occurrence independently selected from 0, 1, 2, 3 or 4;

$R_3$  is at each occurrence independently halogen, hydroxy, carboxy, alkyl, alkoxy, haloalkyl, acyloxy, thioalkyl, sulfinylalkyl, sulfonylalkyl, hydroxyalkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heterocycle, substituted heterocycle, heterocyclealkyl, substituted heterocyclealkyl,  $-C(=O)OR_8$ ,  $-C(=O)R_8$ ,  $-C(O)NR_8R_9$ ,  $-C(=O)NR_8OR_9$ ,  $-SO_2NR_8R_9$ ,  $-NR_8SO_2R_9$ ,  $-CN$ ,  $-NO_2$ ,  $-NR_8R_9$ ,  $-NR_8C(=O)R_9$ ,  $-NR_8C(=O)(CH_2)_bOR_9$ ,  $-NR_8C(=O)(CH_2)_bR_9$ ,  $-O(CH_2)_bNR_8R_9$ , or heterocycle fused to phenyl;

$R_4$  is 3-triazolyl, optionally substituted at its 5-position with:

- (a) methyl, n-propyl, isopropyl, 1-hydroxyethyl, 3-hydroxypropyl, methylaminomethyl, dimethylaminomethyl, 1-(dimethylamino)ethyl, 1-pyrrolidinylmethyl or 2-pyrrolidinyl;

R<sub>5</sub>, R<sub>6</sub> and R<sub>7</sub> are the same or different and at each occurrence independently hydrogen, alkyl, aryl, arylalkyl, heterocycle or heterocyclealkyl, wherein each of R<sub>5</sub>, R<sub>6</sub> and R<sub>7</sub> are optionally substituted with one to four substituents independently selected from R<sub>3</sub>; and

R<sub>8</sub> and R<sub>9</sub> are the same or different and at each occurrence independently hydrogen, alkyl, aryl, arylalkyl, heterocycle, or heterocyclealkyl, or R<sub>8</sub> and R<sub>9</sub> taken together with the atom or atoms to which they are bonded form a heterocycle, wherein each of R<sub>8</sub>, R<sub>9</sub>, and R<sub>8</sub> and R<sub>9</sub> taken together to form a heterocycle are optionally substituted with one to four substituents independently selected from R<sub>3</sub>.

86. The method of claim 47 wherein R<sub>4</sub> is methyl, n-propyl, isopropyl, 1-hydroxyethyl, 3-hydroxypropyl, methylaminomethyl, dimethylaminomethyl, 1-(dimethylamino)ethyl, 1-pyrrolidinylmethyl or 2-pyrrolidinyl.

87. The method of claim 67 wherein R<sub>4</sub> is methyl, n-propyl, isopropyl, 1-hydroxyethyl, 3-hydroxypropyl, methylaminomethyl, dimethylaminomethyl, 1-(dimethylamino)ethyl, 1-pyrrolidinylmethyl or 2-pyrrolidinyl.

88. A composition comprising the compound of claim 5 and a pharmaceutically acceptable carrier.

89. A composition comprising the compound of claim 6 and a pharmaceutically acceptable carrier.

90. ~~A composition comprising the compound of claim 10 and a pharmaceutically acceptable carrier.~~

91. A composition comprising the compound of claim 11 and a pharmaceutically acceptable carrier.

92. A composition comprising the compound of claim 12 and a pharmaceutically acceptable carrier.

93. A composition comprising the compound of claim 13 and a pharmaceutically acceptable carrier.

98. A composition comprising the compound of claim 18 and a pharmaceutically acceptable carrier.

99. A composition comprising the compound of claim 19 and a pharmaceutically acceptable carrier.

100. A composition comprising the compound of claim 20 and a pharmaceutically acceptable carrier.

101. A composition comprising the compound of claim 71 and a pharmaceutically acceptable carrier.

102. A composition comprising the compound of claim 72 and a pharmaceutically acceptable carrier.

103. A composition comprising the compound of claim 73 and a pharmaceutically acceptable carrier.

104. A composition comprising the compound of claim 74 and a pharmaceutically acceptable carrier.

105. A composition comprising the compound of claim 85 and a pharmaceutically acceptable carrier.

106. A compound of claim 6, wherein the compound is:  
3-(2-phenylethynyl)-1H-indazole-5-carboxamide, or a pharmaceutically acceptable salt thereof.

---

107. A compound of claim 10, wherein the compound is:  
1-{(3-(4-fluorophenyl)-1H-indazol-5-yl)carbonyl} piperidine-4-carboxylic acid;  
3-(4-fluorophenyl)(1H-indazol-5-yl) pyrrolidinyl ketone;  
3-(4-fluorophenyl)(1H-indazol-5-yl)piperazinyl ketone;  
1-(3-(4-fluorophenyl)-1H-indazol-5-yl)-2-phenylethan-1-one;  
1-(3-(4-fluorophenyl)-1H-indazol-5-yl)ethan-1-one; or a pharmaceutically acceptable salt thereof.

108. A compound of claim 11, wherein the compound is:  
3-(4-fluorophenyl)-1H-indazole-5-carboxamide;



(3-(4-fluorophenyl)(1H-indazol-5-yl))-N-benzamide;  
 N-(2-(dimethylamino)ethyl)3-(4-fluorophenyl) (1H-indazol-5-yl)carboxamide;  
 methyl 4-((3-(4-fluorophenyl)-1H-indazol-5-yl)carbonylamino)benzoate;  
 4-((3-(4-fluorophenyl)-1H-indazol-5-yl)carbonylamino)benzoic acid;  
 4-((3-(4-fluorophenyl)-1H-indazole-5-yl)carbonylamino)benzamide;  
 (3-(4-fluorophenyl)(1H-indazol-5-yl))-N-(2-pyridyl)carboxamide;  
 (3-(4-fluorophenyl)(1H-indazol-5-yl))-N-(3-pyridyl)carboxamide;  
 (3-(4-fluorophenyl)(1H-indazol-5-yl))-N-(4-pyridyl)carboxamide;  
 tert-butyl 3-((3-(4-fluorophenyl)-1H-indazol-5-yl)carbonylamino)propanoate;  
 (3-(4-fluorophenyl)(1H-indazol-5-yl))-N-(3-hydroxyphenyl)carboxamide;  
 3-((3-(4-fluorophenyl)-1H-Indazol-5-yl)carbonylamino)propanoic acid;  
 (3-(4-fluorophenyl)(1H-indazol-5-yl))-N-(3-nitrophenyl)carboxamide;  
 tert-butyl-2-((3-(4-fluorophenyl)-1H-indazol-5-yl)carbonylamino)acetate;  
 4-((3-(4-fluorophenyl)-1H-indazol-5-yl)carbonylamino)butanoic acid;  
 N-(3-aminophenyl)(3-(4-fluorophenyl)(1H-indazol-5-yl))carboxamide;  
 2-((3-(4-fluorophenyl)-1H-indazol-5-yl)carbonylamino)acetic acid;  
 5-((3-(4-fluorophenyl)-1H-indazol-5-yl)carbonylamino)pentanoic acid;  
 4-(((3-(4-fluorophenyl)-1H-indazol-5-yl)carbonylamino)methyl)benzoic acid;  
 (3-(4-fluorophenyl)(1H-indazol-5-yl))-N-(4-pyridylmethyl)carboxamide;  
 2-(4-((3-(4-fluorophenyl)-1H-indazol-5-yl)carbonylamino)phenyl)acetic acid;  
 (3-(4-fluorophenyl)(1H-indazol-5-yl))-N,N-dimethylcarboxamide;  
 (3-(4-fluorophenyl)(1H-indazol-5-yl))-N-methylcarboxamide;  
 N-(3-aminoethyl)(3-(4-fluorophenyl)(1H-indazol-5-yl))carboxamide;  
 N-(3-aminopropyl)(3-(4-fluorophenyl)(1H-indazol-5-yl))carboxamide;  
 (3-(4-fluorophenyl)(1H-indazol-5-yl))-N-(2-hydroxypropyl)carboxamide;  
 N-(2H-1,2,3,4-tetrazol-5-yl)(3-(4-fluorophenyl)(1H-indazol-5-yl))carboxamide;  
 {3-(4-fluorophenyl)(1H-indazol-5-yl)}-N-(3-morpholin-4-ylpropyl)carboxamide;  
 (3-(4-fluorophenyl)(1H-indazol-5-yl))-N-(3-pyridylmethyl)carboxamide;  
 N-(((2R)-2-hydroxycyclohexyl)methyl)(3-(4-fluorophenyl)(1H-indazole-5-yl)carboxamide;  
 (3-(4-fluorophenyl)(1H-indazol-5-yl))-N-(2-(1-methylimidazol-5-yl)ethyl)carboxamide);  
 (3-(4-fluorophenyl)(1H-indazol-5-yl))-N-(2-pyridylmethyl)carboxamide;

N-(2-carbamoyl-ethyl)(3-(4-fluorophenyl)(1H-indazol-5-yl))carboxamide;  
 N-(3-carbamoyl-propyl)(3-(4-fluorophenyl)(1H-indazol-5-yl))carboxamide;  
 3-(4-methoxyphenyl)-1H-indazole-5-carboxamide;  
 3-(4-hydroxyphenyl)-1H-indazole-5-carboxamide;  
 3-(2-naphthyl)-1H-indazole-5-carboxamide;  
 3-benzo(b)thiophen-2-yl-1H-indazole-5-carboxamide;  
 3-benzo(d)furan-2-yl-1H-indazole-5-carboxamide;  
 3-(3-(methylethyl)phenyl)-1H-indazole-5-carboxamide;  
 3-(4-(dimethylamino)phenyl)-1H-indazole-5-carboxamide;  
 3-(3-furyl)-1H-indazole-5-carboxamide;  
 3-{4-(2-(dimethylamino)ethoxy)phenyl}-1H-indazole-5-carboxamide;  
 3-(3,4-dimethoxyphenyl)-1H-indazole-5-carboxamide;  
 3-(3-aminophenyl)-1H-indazole-5-carboxamide;  
 3-(2H-benzo(d)1,3-dioxolen-5-yl)-1H-indazole-5-carboxamide;  
 (3-benzo(d)furan-2-yl(1H-indazol-5-yl))-N-(methylethyl)carboxamide;  
 (3-benzo(d)furan-2-yl(1H-indazol-5-yl))-N-(2-methoxyethyl)carboxamide;  
 (3-benzo(d)furan-2-yl(1H-indazol-5-yl))-N-(2-(dimethylamino)ethyl)carboxamide;  
 (3-benzo(d)furan-2-yl(1H-indazol-5-yl))-N-(4-(dimethylamino)butyl)carboxamide;  
 (3-benzo(d)furan-2-yl(1H-indazol-5-yl))-N-(3-(dimethylamino)propyl)carboxamide;  
 (3-benzo(d)furan-2-yl(1H-indazol-5-yl))-N-(2-methylpropyl)carboxamide;  
 (3-benzo(d)furan-2-yl(1H-indazol-5-yl))-N-methylcarboxamide;  
 3-(3-(3-pyridylcarbonylamino)phenyl)-1H-indazole-5-carboxamide;  
 3-(3-(2-methoxyacetyl-amino)phenyl)-1H-indazole-5-carboxamide;  
 3-(3-(4-piperidylcarboxyamino)phenyl)-1H-indazole-5-carboxamide;  


---

 (1S)-1-{N-(3-(5-carbamoyl(1H-indazol-3-yl))phenyl)carbamoyl}ethyl acetate;  
 3-{3-(2-methoxyethyl-amino)phenyl}-1H-indazole-5-carboxamide;  
 3-(3-(3-piperidylpropanoylamino)phenyl)-1H-indazole-5-carboxamide;  
 3-(3-(2-furylcarbonylamino)phenyl)-1H-indazole-5-carboxamide;  
 3-{3-(2-(dimethylamino)acetyl-amino)phenyl}-1H-indazole-5-carboxamide;  
 3-(3-(2-phenylacetyl-amino)phenyl)-1H-Indazole-5-carboxamide;  
 3-{3-(2-(4-methoxyphenyl)acetyl-amino)phenyl}-1H-indazole-5-carboxamide;  
 3-{3-(2-(2-methyl-1,3-thiazol-5-yl)acetyl-amino)phenyl}-1H-indazole-5-carboxamide;

3-(3-(oxolan-3-yl-carbonylamino)phenyl)-1H-indazole-5-carboxamide;  
 3-(3-(2-(3-thienyl)acetylaminophenyl)-1H-indazole-5-carboxamide;  
 3-(3-(2-thienylcarbonylamino)phenyl)-1H-indazole-5-carboxamide;  
 3-(3-(2-(4-pyridyl)acetylaminophenyl)-1H-Indazole-5-carboxamide;  
 3-(3-(2-(2-pyridyl)acetylaminophenyl)-1H-Indazole-5-carboxamide;  
 3-{3-(2-(4-fluorophenyl)acetylaminophenyl)}-1H-indazole-5-carboxamide;  
 3-(3-(cyclopropylcarbonylamino)phenyl)-1H-indazole-5-carboxamide;  
 3-{3-((3-hydroxyphenyl)carbonylamino)phenyl}-1H-indazole-5-carboxamide;  
 3-{3-(2-(2,4-dichlorophenyl)acetylaminophenyl)}-1H-indazole-5-carboxamide;  
 3-(3-{2-(4-(trifluoromethyl)phenyl)acetylaminophenyl}-1H-indazole-5-carboxamide;  
 3-(3-{2-(4-(dimethylamino)phenyl)acetylaminophenyl}-1H-indazole-5-carboxamide;  
 3-{3-(2-(2-chloro-4-fluorophenyl)acetylaminophenyl)}-1H-indazole-5-carboxamide;  
 3-{3-(2-(4-chlorophenyl)acetylaminophenyl)}-1H-indazole-5-carboxamide;  
 3-(3-(3-phenylpropanoylamino)phenyl)-1H-indazole-5-carboxamide;  
 3-{3-(3-(4-fluorophenyl)propanoylamino)phenyl}-1H-indazole-5-carboxamide;  
 3-{3-(2-(3,4-difluorophenyl)acetylaminophenyl)}-1H-indazole-5-carboxamide;  
 3-{3-(2-(2-fluorophenyl)acetylaminophenyl)}-1H-indazole-5-carboxamide;  
 3-(3-(2-phenylpropanoylamino)phenyl)-1H-indazole-5-carboxamide;  
 3-(3-(2-piperidylethoxy)phenyl)-1H-indazole-5-carboxamide;  
 N-ethyl-3-((3-(4-fluorophenyl)(1H-indazol-5-yl))carbonylamino)propanamide;  
 (3-(4-fluorophenyl)(1H-indazol-5-yl))-N=(3-methoxypropyl)carboxamide;  
 3-{3-(N-(2-piperidylethyl)carbonyl)phenyl}-1H-indazole-5-carboxamide;  
 (3-(4-fluorophenyl)(1H-indazol-5-yl))-N-(2-hydroxyethyl)carboxamide;  
 (3-(4-fluorophenyl)(1H-indazol-5-yl))-N-(3-hydroxypropyl)carboxamide;  
 (3-(4-fluorophenyl)(1H-indazol-5-yl))-N-(2-methoxyethyl)carboxamide;  
 (3-(4-fluorophenyl)(1H-indazol-5-yl))-N-(oxolan-2-ylmethyl)carboxamide;  
 3-(2H, 3H-benzo(e)1,4-dioxin-6-yl)-1H-indazole-5-carboxamide;  
 3-(3-quinolyl)-1H-indazole-5-carboxamide;  
 3-(6-methoxy-2-naphthyl)-1H-indazole-5-carboxamide;  
 3-(2,3-dihydrobenzo(b)furan-5-yl)-1H-indazole-5-carboxamide;

(3-(4-fluorophenyl)(1H-indazol-5-yl))-N-(3-oxo-3-pyrrolidinylpropyl) carboxamide;  
 3-{(3-(4-fluorophenyl)(1H-indazol-5-yl))carbonylamino}-N-methyl propanamide;  
 3-{(3-(4-fluorophenyl)(1H-indazol-5-yl))carbonylamino}-N,N-dimethyl  
 propanamide;  
 3-{(3-(4-fluorophenyl)(1H-indazol-5-yl))carbonylamino}-N-(2-  
 methoxyethyl)propanamide; or a pharmaceutically acceptable salt thereof.

109. A compound of claim 12, wherein the compound is:  
 phenyl-N-(3-phenyl(1H-indazol-5-yl))carboxamide;  
 N-(3-phenyl(1H-indazol-5-yl))-2-pyridylcarboxamide;  
 methyl 4-(N-(3-phenyl-1H-indazol-5-yl)carbamoyl)benzoate;  
 4-(N-(3-phenyl-1H-indazol-5-yl)carbamoyl)benzoic acid;  
 (2-hydroxyphenyl)-N-(3-phenyl(1H-indazol-5-yl))carboxamide;  
 N-(3-(phenyl-1H-indazole-5-yl))acetamide;  
 (4-aminophenyl)-N-(3-phenyl(1H-indazol-5-yl))carboxamide;  
 (3-aminophenyl)-N-(3-phenyl(1H-indazol-5-yl))carboxamide;  
 N-(3-(4-fluorophenyl)(1H-indazol-5-yl))(2-methylphenyl)carboxamide;  
 N-(3-(4-fluorophenyl)(1H-indazol-5-yl))(2-methoxyphenyl)carboxamide;  
 N-(3-(4-fluorophenyl)(1H-indazol-5-yl))(4-phenylphenyl)carboxamide;  
 benzo(b)thiophen-2-yl-N-(3-(4-fluorophenyl)(1H-indazol-5-yl))carboxamide;  
 methyl 4-{N-(3-(4-fluorophenyl)-1H-indazol-5-yl)carbamoyl}benzoate;  
 N-(3-(4-fluorophenyl)(1H-indazol-5-yl))-2-pyridylcarboxamide;  
 4-{N-(3-(4-fluorophenyl)-1H-indazol-5-yl)carbamoyl}benzoic acid;  
 cyclopropyl-N-(3-(4-fluorophenyl)(1H-indazol-5-yl))carboxamide;  
 methyl 4-{N-(3-(4-fluorophenyl)(1H-indazol-5-yl))-N-methylcarbamoyl}benzoate;  
 4-{N-(3-fluorophenyl)(1H-indazol-5-yl))-N-methylcarbamoyl}benzoic acid;  
 methyl 3-{N-((4-fluorophenyl)-1H-indazol-5-yl)carbamoyl}benzoate;  
 3-{N-(3-(4-fluorophenyl)-1H-indazol-5-yl)carbamoyl}benzoic acid;  
 N-(3-(4-fluorophenyl)-(1H-indazol-5-yl))(4-(N-  
 methylcarbamoyl)phenyl)carboxamide;  
 4-{N-(3-(4-fluorophenyl)-1H-indazol-5-yl)carbamoyl}benzamide;  
 1-4-{N-(3-(4-methoxyphenyl)-1H-indazol-5-yl)carbamoyl}benzoic acid;  
 4-(N-(3-(4-pyridyl)-1H-indazol-5-yl)carbamoyl)benzoic acid;  
 N-(3-(4-fluorophenyl)(1H-indazol-5-yl))benzamide;

(3,4-bis(trifluoromethyl)phenyl)-N-(3-(4-fluorophenyl)(1H-indazol-5-yl))carboxamide;  
 N-(3-(4-fluorophenyl)(1H-indazol-5-yl))-2-furylcarboxamide;  
 N-(3-(4-fluorophenyl)(1H-indazol-5-yl))(3,4-dichlorophenyl)carboxamide;  
 N-(3-(4-fluorophenyl)(1H-indazol-5-yl))(2-hydroxyphenyl)carboxamide;  
 N-(3-(4-fluorophenyl)(1H-indazol-5-yl))-4-pyridylcarboxamide;  
 N-(3-(4-fluorophenyl)(1H-indazol-5-yl))-3-pyridylcarboxamide;  
 N-(3-(4-fluorophenyl)(1H-indazol-5-yl))-2-thienylcarboxamide;  
 N-(3-(4-fluorophenyl)(1H-indazol-5-yl))morpholin-4-yl-carboxamide;  
 [N-(((2R)-2-hydroxycyclohexyl)methyl) (3-(4-fluorophenyl) (1H-indazol-5-yl))carboxamide;] or a pharmaceutically acceptable salt thereof.

110. A compound of claim 13, wherein the compound is:  
 (3-(4-fluorophenyl)(1H-indazol-5-yl))(4-pyridylmethyl)amine;  
 (3-(4-fluorophenyl)(1H-indazol-5-yl))(3-pyridylmethyl)amine; or a pharmaceutically acceptable salt thereof.

114. A compound of claim 18, wherein the compound is:  
 3-(3-(4-fluorophenyl)-1H-indazol-5-yl)-1H-1,2,4-triazole;  
 5-(3-(4-fluorophenyl)(1H-indazole-5-yl))-3-methyl-4H-1,2,4-triazole;  
 5-{3-(4-fluorophenyl)(1H-indazole-5-yl)}-3-(methylethyl)-4H-1,2,4-triazole;  
 1-{5-(3-(4-fluorophenyl)-1H-indazole-5-yl)-4H-1,2,4-triazol-3-yl} propan-2-ol;  
 5-(3-(4-fluorophenyl)(1H-indazol-5-yl))-3-propyl-4H-1,2,4-triazole;  
 5-{3-(3-(methylethyl)phenyl)-1H-indazol-5-yl}-1H-1,2,4-triazole;  
 4-(5-(1H-1,2,4-triazol-5-yl)-1H-indazol-3-yl)phenol;  
 (4-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))phenyl)dimethylamine;  
 {2-(4-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))phenoxy)ethyl} dimethylamine;  
 3-(5-(1H-1,2,4-triazol-5-yl)-1H-indazol-3-yl)furan;  
 1-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))-4-methoxybenzene;  
 5-(3-naphthyl-1H-indazol-5-yl)-1H-1,2,4-triazole;  
 3-(5-(1H-1,2,4-triazol-3-yl)-1H-indazol-3-yl)thiophene;  
 5-(3-(2-naphthyl)-1H-indazol-5-yl)-1H-1,2,4-triazole;  
 3-(5-(1H-1,2,4-triazol-3-yl)-1H-indazol-3-yl)phenylamine;  
 3-(3-(3,4-dichlorophenyl)-1H-indazol-5-yl)-1H-1,2,4-triazole;

3-(5-(1H-1,2,4-triazol-5-yl)-1H-indazol-3-yl)benzo(b)thiophene;  
 3-(3-(4-methylphenyl)-1H-indazol-5-yl)-1H-1,2,4-triazole;  
 N-(3-(5-(1H-1,2,4-triazol-3-yl)-1H-indazol-3-yl)phenyl)acetamide;  
 5-(3-(3-chlorophenyl)-1H-indazol-5-yl)-1H-1,2,4-triazole;  
 2-(5-(1H-1,2,4-triazol-5-yl)-1H-indazol-3-yl)benzo(b)furan;  
 1-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))-4-(methylsulfonyl)benzene;  
 1-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))-4-(methylsulfinyl)benzene;  
 5-(5-(1H-1,2,4-triazol-5-yl)-1H-indazol-3-yl)-2H-benzo(d)1,3-dioxolene;  
 4-(5-(1H-1,2,4-triazol-5-yl)-1H-indazol-3-yl)phenylamine;  
 5-{3-(4-(trifluoromethyl)phenyl)-1H-indazol-5-yl}-1H-1,2,4-triazole;  
 (3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl)) phenyl) (methylsulfonyl)amine;  
 N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-2-methoxyacetamide;  
 N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-2-phenylacetamide;  
 N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-2-furylcarboxamide;  
 5-(3-(2-phenylethynyl)-1H-indazol-5-yl)-1H-1,2,4-triazole;  
 N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-3-pyridylcarboxamide;  
 1-{5-{3-(4-fluorophenyl)1H-indazol-5-yl}-4H-1,2,4-Triazol-3-yl} ethan-1-ol;  
 1-{5-(3-(4-fluorophenyl)-1H-indazol-5-yl)-4H-1,2,4-triazol-3-yl}propan-2-ol;  
 {3-(3-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))phenoxy)propyl} dimethylamine;  
 {2-(3-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))phenoxy)ethyl} dimethylamine;  
 1-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))-3-(2-morpholin-4-yl-ethoxy)benzene;  
 1-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))-3-(2-pyrrolidinylethoxy) benzene;  
 1-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))-3-(2-piperidylethoxy) benzene;  
 1-{2-(3-(5-(1H-1,2,4-triazol-5-yl)-1H-indazol-3-yl)phenoxy)ethyl}-pyrrolidin-2-

one;

1-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))-3-(2-piperazinylethoxy) benzene;  
 1-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))-3-(3-piperidylpropoxy) benzene;  
 4-{2-(3-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))phenoxy)ethyl}-1-acetyl-  
 piperazine;  
 2-(3-(5-(1H-1,2,4-triazol-5-yl)-1H-indazol-3-yl)phenoxy)ethylamine;  
 1-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))-3-(2-cyclohexylethoxy) benzene;  
 1-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))-3-(2-azaperhydropyridylethoxy)benzene;

N-(4-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))phenyl)-2-furyl caroxamide;  
 (3-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))phenyl)-N-benzyl caroxamide;  
 5-(3-(2-chlorophenyl)-1H-indazol-3-yl)-1H-1,2,4-triazole;  
 (3-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))phenyl)-N-(2,2-dimehtylpropyl)carboxamide;  
 (3-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))phenyl)-N-(cyclopropylmethyl)carboxamide;  
 (3-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))phenyl)-N-(3-pyridylmethyl)carboxamide;  
 (3-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))phenyl)-4-methyl piperazinyl ketone;  
 (3-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))phenyl)-N-((4-fluorophenyl)methyl)carboxamide;  
 (3-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))phenyl)-N-indan-2-ylcarboxamide;  
 (3-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))phenyl)-N-((1R)indanyl)carboxamide;  
 (3-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))phenyl)-N-((1S)indanyl)carboxamide;  
 (3-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))phenyl)-N-((1S,2R)-2-hydroxyindanyl)carboxamide;  
 (3-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))phenyl)-N-((2S,1R)-2-hydroxyindanyl)carboxamide;  
 (3-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))phenyl)-N-(1-methyl-1-phenylethyl)carboxamide;  
 (3-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))phenyl)-N-(tert-butyl)carboxamide;  
 (3-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))phenyl)-N-((1R)-1-phenylethyl)carboxamide;  
 1-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))-3-(2-piperidylethoxy) benzene;  
 (3-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))phenyl)-isoindolin-2-yl ketone;  
 (3-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))phenyl)-N-(2-(dimethylamino)ethyl)carboxamide;  
 1-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))-3-(2-piperidylethoxy) benzene;  
 (3-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))phenyl)-N-(1R)indanyl benzene;

{5-(3-(4-fluorophenyl)-1H-indazol-5-yl)-4H-(1,2,4)-triazol-3-ylmethyl}-dimethylamine;

N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-3-piperidylpropanamide;

N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-2-hydroxypropanamide;

N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-2-

(dimethylamino)acetamide;

N-(3-(5-(1H-1,2,4-triazol-3-yl)-1H-indazol-3-yl)phenyl)butanamide;

N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-2-phenoxypropanamide;

N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-3,3-dimethylbutanamide;

N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)cyclopropylcarboxamide;

N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)(6-chloro(3-

pyridyl))carboxamide;

N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)cyclopentylcarboxamide;

N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)benzo(b)thiophen-2-

carboxamide;

N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-2-pyridylcarboxamide;

N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-3-furylcarboxamide;

N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-2-hydroxy-2-

phenylacetamide;

N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)isoxazol-5-ylcarboxamide;

N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)pentanamide;

N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-4-pyridylcarboxamide;

N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-2-cyclohexylacetamide;

N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-3-propanamide;

N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-2-(4-fluorophenyl)acetic acid;

N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)(2R)-2-hydroxy-2-phenylacetamide;

N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)(2S)-2-hydroxy-2-phenylacetamide;

(2-{3-(3-(4-fluorophenyl)(1H-indazol-5-yl))(1H-1,2,4-triazol-5-yl)}ethyl)dimethylamine;



diethyl({3-(3-(4-fluorophenyl)(1H-indazol-5-yl))(1H-1,2,4-triazol-5-yl)}methyl)amine;  
 ({3-(3-(4-fluorophenyl)(1H-indazol-5-yl))(1H-1,2,4-triazol-5-yl)}methyl)methylamine;  
 ({3-(3-(4-fluorophenyl)(1H-indazol-5-yl))(1H-1,2,4-triazol-5-yl)}ethyl)dimethylamine;  
 (2R)-N-(3-(5-{5-((dimethylamino)methyl)(1H-1,2,4-triazol-3-yl)}(1H-indazol-3-yl))phenyl)-2-hydroxy-2-phenylacetamide;  
 N-(3-(5-{5-((dimethylamino)methyl)(1H-1,2,4-triazol-3-yl)}(1H-indazol-3-yl))phenyl)-3,3-dimethylbutanamide;  
 N-(3-(5-{5-((dimethylamino)methyl)(1H-1,2,4-triazol-3-yl)}(1H-indazol-3-yl))phenyl)-3-methylbutanamide;  
 N-(3-(5-{5-((dimethylamino)methyl)(1H-1,2,4-triazol-3-yl)}(1H-indazol-3-yl))phenyl)-3-pyridylcarboxamide;  
 (3-(5-{5-((dimethylamino)methyl)(1H-1,2,4-triazol-3-yl)}(1H-indazol-3-yl))phenyl)-N-((4-fluorophenyl)methyl)carboxamide;  
 (3-(5-{5-((dimethylamino)methyl)(1H-1,2,4-triazol-3-yl)}(1H-indazol-3-yl))phenyl)-N-((*tert*-butyl)methyl)carboxamide;  
 ((1R)indanyl)(3-(5-{5-((dimethylamino)methyl)(1H-1,2,4-triazol-3-yl)}(1H-indazol-3-yl))phenyl)carboxamide;  
 ({3-(3-(4-methoxyphenyl)(1H-indazol-5-yl))(1H-1,2,4-triazol-5-yl)}methyl)dimethylamine;  
 ({3-(3-(2H-benzo(d)1,3-dioxolen-5-yl))(1H-indazol-5-yl))(1H-1,2,4-triazol-5-yl)}methyl}dimethylamine;  


---

 (3-(5-(3-((dimethylamino)methyl)(1H-1,2,4-triazol-5-yl))(1H-indazol-3-yl))phenyl)-N-(2-piperidylethyl)carboxamide;  
 ((5-(3-benzo(D)furan-2-yl)(1H-indazol-5-yl))(1H-1,2,4-triazol-3-yl)methyl)dimethylamine;  
 (3-(5-(3-((dimethylamino)methyl)(1H-1,2,4-triazol-5-yl))(1H-indazol-3-yl))phenyl)-N-benzamide;  
 (3-(5-(3-((dimethylamino)methyl)(1H-1,2,4-triazol-5-yl))(1H-indazol-3-yl))phenyl)-N-(4-fluorophenyl)carboxamide-2HCl;

(3-(5-(3-((dimethylamino)methyl)(1H-1,2,4-triazol-5-yl))(1H-indazol-3-yl))phenyl)-N-indan-2-yl-carboxamide;

(3-(5-(3-((dimethylamino)methyl)(1H-1,2,4-triazol-5-yl))(1H-indazol-3-yl))phenyl)-N-cyclopropylcarboxamide;

(3-(5-(3-((dimethylamino)methyl)(1H-1,2,4-triazol-5-yl))(1H-indazol-3-yl))phenyl)-N-cyclobutylcarboxamide-2HCl;

1-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl)-3-(2-methoxyethoxy)benzene;

1-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl)-3-(3-pyridylmethoxy)benzene;

3-(5-(1H-1,2,4-triazol-3-yl)-1H-indazol-3-yl)benzoic acid;

3-(5-(1H-1,2,4-triazol-3-yl)-1H-indazol-3-yl)benzoic acid N-(4-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-2-(3-pyridyl)acetamide;

N-(4-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-2-phenylacetamide;

N-(4-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-2-methoxyacetamide;

N-(4-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-2-(dimethylamino)acetamide;

(4-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)(methylsulfonyl)amine;

(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-N-(2-methoxyethyl)carboxamide;

(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-N-benzamide;

(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-N-(2-phenethyl)carboxamide;

(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-N-(2-piperidylethyl)carboxamide;

(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-N-(2-morpholin-4-ylethyl)carboxamide;

(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-N-cyclohexylcarboxamide;

(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-N-cyclopentylcarboxamide;

(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-N-(4-fluorophenyl)carboxamide;

(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-N-((1R,2R)-2-phenylcyclopropyl) carboxamide;

(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-N-cyclopropylcarboxamide;

(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-N-(3-pyridyl)carboxamide;

(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl-N-(5,6,7,8-tetrahydronaphthyl)carboxamide;

(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl-N-(1-benzyl(4-piperidyl))carboxamide;

(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl-N-(1-benzylpyrrolidin-3-yl)carboxamide;

(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl-N-(methylethyl)carboxamide;

(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl-N-cyclobutylcarboxamide;

(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl-N-(4-pyridyl)carboxamide;

6-(5-(1H-1,2,4-triazol-3-yl)-1H-indazol-3-yl)-2H,3h-benzo(e)1,4-dioxin;

6-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))-2-methoxynaphthalene;

3-(3-(3-quinoyl)-1H-indazol-5-yl)-1H-1,2,4-triazole;

5-(5-(1H-1,2,4-triazol-3-yl)-1H-indazol-3-yl)-2,3-dihydrobenzo(b)furan;

N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)benzamide;

N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)(2,4-dichlorophenyl)carboxamide;

N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)(4-methoxyphenyl)carboxamide;

N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)(4-methylphenyl)carboxamide;

N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)(4-chlorophenyl)carboxamide;

N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-2-methylpropanamide;

N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-3-methylbutanamide;

---

N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-2-morpholin-4-yl-acetamide;

N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-2-(4-methylpiperazinyl)acetamide;

2-methoxy-6-{5-(5-(pyrrolidinylmethyl)(1H-1,2,4-triazol-3-yl))(1H-indazol-3-yl)}naphthalene;

N-phenyl(3-{5-(5-(pyrrolidinylmethyl)(1H-1,2,4-triazol-3-yl))(1H-indazol-3-yl)}phenyl)carboxamide;

6-{5-(5-(pyrrolidinylmethyl)-1H-1,2,4-triazol-3-yl)-1H-indazol-3-yl}-2H,3H-benzo(e)1,4-dioxin; or a pharmaceutically acceptable salt thereof.

115. A compound of claim 19, wherein the compound is:

5-(3-(4-fluorophenyl)-1H-indazol-5-yl)-2H-1,2,3,4-tetrazole;

1-(5-(2H-1,2,3,4-tetrazol-5-yl)(1H-indazol-3-yl))-2-methoxybenzene;

5-(3-(3-pyridyl)-1H-indazol-5-yl)-2H-1,2,3,4-tetrazole;

2-(5-(2H-1,2,3,4-tetrazol-5-yl)-1H-indazol-3-yl)thiophene;

5-{3-(4-(methylethyl)phenyl)-1H-indazol-5-yl}-2H-1,2,3,4-tetrazole;

2-(5-(2H-1,2,3,4-tetrazol-5-yl)-1H-indazol-3-yl)furan;

3-(5-(2H-1,2,3,4-tetrazol-5-yl)-1H-indazol-3-yl)phenylamine;

5-(5-(1H-1,2,3,4-tetraazol-5-yl)-1H-indazol-3-yl)-2H-benzo(d)1,3-dioxolene;

3-(5-(2H-1,2,3,4-tetrazol-5-yl)-1H-indazol-3-yl)thiophene;

5-(3-(2-naphthyl)-1H-indazol-5-yl)-1H-1,2,3,4-tetrazole;

1-(5-(1H-1,2,3,4-tetraazol-5-yl)(1H-indazol-3-yl))-4-methoxybenzene;

1-(5-(1H-1,2,3,4-tetraazol-5-yl)(1H-indazol-3-yl))-4-(2-methylpropoxy)benzene;

5-(3-(4-chlorophenyl)-1H-indazol-5-yl)-2H-1,2,3,4-tetrazole;

1-(5-(2H-1,2,3,4-tetrazol-5-yl)(1H-indazol-3-yl))-3-methoxybenzene;

5-(3-(4-pyridyl)-1H-indazol-5-yl)-2H-1,2,3,4-tetrazole;

2-(5-(2H-1,2,3,4-tetraazol-5-yl)-1H-indazol-3-yl)benzo(b)furan;

2-(5-(2H-1,2,3,4-tetrazol-5-yl)-1H-indazol-3-yl)phenol;

3-(5-(2H-1,2,3,4-tetrazol-5-yl)-1H-indazol-3-yl)phenol;

5-(3-(2-phenylethynyl)-1H-indazol-5-yl)-1H-1,2,3,4-tetrazole;

5-(3-(2-phenylethyl)-1H-indazol-5-yl)-2H-1,2,3,4-tetrazole;

---

N-(3-(5-(2H-1,2,3,4-tetrazol-5-yl)(1H-indazol-3-yl))phenyl)-2-methoxyacetamide;

2-(5-(1H-1,2,3,4-tetraazol-5-yl)-1H-indazol-3-yl)benzo(b)thiophene;

1-(5-(1H-1,2,3,4-tetraazol-5-yl)(1H-indazol-3-yl))-4-(2-morpholin-4-ylethoxy)benzene;

N-(3-(5-(2H-1,2,3,4-tetrazol-5-yl)(1H-indazol-3-yl))phenyl)-2-phenoxypropanamide;

N-(3-(5-(2H-1,2,3,4-tetrazol-5-yl)(1H-indazol-3-yl))phenyl)-3-piperidylpropanamide;

N-(3-(5-(2H-1,2,3,4-tetrazol-5-yl)(1H-indazol-3-yl))phenyl)-2-furylcarboxamide;

1-(5-(1H-1,2,3,4-tetraazol-5-yl)(1H-indazol-3-yl))-3-(2-morpholin-4-ylethoxy)benzene;

4-(5-(2H-1,2,3,4-tetrazol-5-yl)(1H-indazol-3-yl))-1,2-dimethoxybenzene;  
 N-(3-(5-(2H-1,2,3,4-tetrazol-5-yl)(1H-indazol-3-yl))phenyl)-3-methoxypropanamide;  
 N-(3-(5-(2H-1,2,3,4-tetrazol-5-yl)(1H-indazol-3-yl))phenyl)-3-pyridylcarboxamide;  
 {3-(4-(5-(1H-1,2,3,4-tetrazo-5-yl)(1H-indazol-3-yl))phenoxy)propyl} dimethylamine;  
 {3-(3-(5-(1H-1,2,3,4-tetrazol-5-yl)(1H-indazol-3-yl))phenoxy)propyl} dimethylamine;  
 {2-(3-(5-(1H-1,2,3,4-tetrazol-5-yl)(1H-indazol-3-yl))phenoxy)ethyl} dimethylamine;  
 N-(3-(5-(2H-1,2,3,4-tetrazol-5-yl)(1H-indazol-3-yl))phenyl)(2S)-2-hydroxypropanamide;  
 N-(4-(5-(2H-1,2,3,4-tetrazo-5-yl)(1H-indazol-3-yl))phenyl)-3-pyridylcarboxamide;  
 or a pharmaceutically acceptable salt thereof.

116. A compound of claim 20, wherein the compound is:

3-(4-fluorophenyl)-5-imidazol-2-yl-1H-indazole, or a pharmaceutically acceptable salt thereof.

117. A compound, wherein the compound is:

3-phenyl-5-(phenylmethoxy)-1H-indazole;  
 (3-(4-fluorophenyl)(1H-indazol-5-yl))(phenylsulfonyl)amine;  
 3-(4-fluorophenyl)-1H-indazole-5-carboxylate;  
 (3-(4-fluorophenyl)(1H-indazol-5-yl))-N-(phenylmethoxy)carboxamide;  
 3-(4-fluorophenyl)-1H-indazole-5-carbohydroxamic acid;  
 N-(((tert-butoxy)carbonylamino)-(3-(4-fluorophenyl)-(1H-indazol-5-yl))carboxamide;  
 N-amino(3-(4-fluorophenyl)(1H-indazol-5-yl))carboxamide;  
 methyl-3-benzo(B)thiophen-2-yl-1H-indazole-5-carboxylate;  
 3-benzo(B)thiophen-2-yl-1H-indazole-5-carboxylic acid; or a pharmaceutically acceptable salt thereof.

118. (New) A compound, wherein the compound is:

ethyl 1-{(3-(4-fluorophenyl)-1H-indazol-5-yl)carbonyl}piperidine-4-carboxylate;  
 2-{N-(3-(4-fluorophenyl)-1H-indazol-5-yl)carbonyl}phenyl methyl benzoate;  
 N-(3-(4-fluorophenyl)(1H-indazol-5-yl))((4-fluorophenyl)amino)carboxamide;

5-nitro-3-phenyl-1H-indazole;  
 5-amino-3-phenyl-1H-indazole;  
 N-{2-(3-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))phenoxy)ethyl}  
 (phenylmethoxy) carboxamide;  
 N-{2-(3-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))phenoxy)ethyl}acetamide;  
 2E-N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-3-phenylprop-2-  
 enamide;  
 N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-2-indol-3-yl-2-  
 oxoacetamide;  
 N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)methane carboxylic acid;  
 N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-2-(2-furyl)-2-  
 oxoacetamide;  
 N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-2-oxo-2-phenylacetamide;  
 (3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-N-{2-(1-benzyl(4-  
 piperidyl))ethyl}carboxamide;  
 (1S)-1-{N-(3-(5-(2H-1,2,3,4-tetrazol-5-yl)(1H-indazol-3-yl))phenyl)  
 carbamoyl}ethyl acetate;  
 or a pharmaceutically acceptable salt thereof.

119. (New) A compound, wherein the compound is:  
 3-phenyl-5-trifluoromethyl-1H-indazole;  
 5-methyl-3-phenyl-1H-indazole;  
 3-(4-fluorophenyl)-5-pyrazol-3-yl-1H-indazole;  
 5-benzimidazol-2-yl-3-(4-fluorophenyl)-1H-indazole;  


---

 5-{3-(4-fluorophenyl)(1H-indazole-5-yl))-3-phenyl-4H-1,2,4-triazole;  
 2-{5-(3-(4-fluorophenyl)-1H-indazol-5-yl)-4H-1,2,4-triazol-3-yl} furan;  
 5-(3-(4-fluorophenyl)(1H-indazol-5-yl))-3-(4-pyridyl)-4H-1,2,4-triazole;  
 3-(4-chlorophenyl)-5-(3-(4-fluorophenyl)(1H-indazol-5-yl))-4H-1,2,4-triazole;  
 5-(3-(4-fluorophenyl)(1H-indazole-5-yl))-3-(4-nitrophenyl)-4H-1,2,4-triazole;  
 1-{5-(3-(4-fluorophenyl)(1H-indazol-5-yl))(4H-1,2,4-triazol-3-yl))-4-  
 methoxybenzene;  
 4-{5-(3-(4-fluorophenyl)-1H-indazol-5-yl)-4H-1,2,4-triazol-3-yl}phenylamine;  
 5-(3-(4-fluorophenyl)(1H-indazol-5-yl))-3-benzyl-4H-1,2,4-triazole;  
 2-(3-(4-fluorophenyl)(1H-indazol-5-yl))-5-phenyl-1,3,4-oxadiazole;

5-(3-(4-fluorophenyl)(1H-indazol-5-yl))-2-methyl-1,3,4-oxadiazole;  
 ethyl (2E)-3-(3-(4-fluorophenyl)-1H-indazol-5-yl)prop-2-enoate;  
 3-(3-(4-fluorophenyl)-1H-indazol-5-yl)propanoic acid;  
 5-(3-(4-fluorophenyl)(1H-indazol-5-yl))-3-(3-pyridyl)-4H-1,2,4-triazole;  
 4-{5-(3-(4-fluorophenyl)-1H-indazol-5-yl)-4H-1,2,4-triazol-3-yl} phenol;  
 2-{5-(3-(4-fluorophenyl)-1H-indazol-5-yl)-4H-1,2,4-triazol-3-yl} acetic acid;  
 ethyl 3-{5-{3-(4-fluorophenyl)-1H-indazol-5-yl)-4H-1,2,4-triazol-3-yl}propanoate;  
 ethyl-4-{5-(3-(4-fluorophenyl)-1H-indazol-5-yl)-4H-1,2,4-triazol-3-yl}butanoate;  
 3-{5-(3-(4-fluorophenyl)-1H-indazol-5-yl)-4H-1,2,4-triazol-3-yl}propanoic acid;  
 5-methyl-3-(4-fluorophenyl)-1H-indazole;  
 3-(3-(4-fluorophenyl)-1H-indazol-5-yl)-1,2,4-oxadiazolin-5-one;  
 3-(4-fluorophenyl)-5-(2-phenylethynyl)-1H-indazole;  
 5-((1E)-2-phenylvinyl)-3-(4-fluorophenyl)-1H-indazole;  
 5-((1E)-2-(2-pyridyl)vinyl)-3-(4-fluorophenyl)-1H-indazole;  
 4-{(1E)-2-((3-(4-fluorophenyl)-1H-indazol-5-yl)vinyl)} benzoic acid;  
 5-((1E)-2-(3-nitrophenyl)vinyl)-3-(4-fluorophenyl)-1H-indazole;  
 5-((1Z)-2-phenylvinyl)-3-(4-fluorophenyl)-1H-indazole;  
 5-((1E)-2-(4-aminophenyl)vinyl)-3-(4-fluorophenyl)-1H-indazole;  
 5-((1E)-2-(4-pyridyl)vinyl)-3-(4-fluorophenyl)-1H-indazole;  
 (2E)-3-(3-(4-fluorophenyl)-1H-indazol-5-yl)prop-2-enoic acid;  
 5-(2-(3-aminophenyl)ethyl)-3-(4-fluorophenyl)-1H-indazole;  
 4-{2-(3-(4-fluorophenyl)-1H-indazol-5-yl)ethyl} benzoic acid;  
 3-(4-fluorophenyl)-5-(2-(2-pyridyl)ethyl)-1H-indazole;  
 3-(4-fluorophenyl)-5-(2-phenylethyl)-1H-indazole;  
 1-(3-(4-fluorophenyl)-1H-indazol-5-yl)-2-phenylethan-1-ol;  
 4-(3-(4-fluorophenyl)-1H-indazole-5-yl)pyrimidine-2-ylamine;  
 5-(3-(4-fluorophenyl)-1H-indazol-5-yl)-4H-1,2,4-triazole-3-yl-amine;  
 1-({5-(3-(4-fluorophenyl)-1H-indazol-5-yl)-4H-1,2,4-triazol-3-yl} methyl)piperidin-4-ol;  
 1-acetyl-4-({5-(3-(4-fluorophenyl)(1H-indazol-5-yl))(4H-1,2,4-triazol-3-yl)} methyl)piperazine;  
 3-(3-(4-fluorophenyl)(1H-indazol-5-yl))-5-(piperidylmethyl)-1H-1,2,4-triazole;

4-({3-(3-(4-fluorophenyl)(1H-indazol-5-yl))-1H-1,2,4-triazol-5-yl}methyl)morpholine;  
 4-({5-(3-(4-fluorophenyl)-1H-indazol-5-yl)-1,3,4-oxadiazol-2-yl}methyl)morpholine;  
 1-({3-(3-(4-fluorophenyl)-1H-indazol-5-yl)-1H-1,2,4-triazol-5-yl}methyl)pyrrolidine-2-one;  
 (5-(3-(4-fluorophenyl)-1H-indazol-5-yl)-1H-1,2,4-triazol-3-yl)methan-1-ol;  
 3-(3-(4-fluorophenyl)(1H-indazol-3-yl))-5-((4-pyrrolidinylpiperidyl) methyl)-1H-1,2,4-triazole;  
 3-(3-((1E)-2-phenylvinyl)-1H-indazol-5-yl)-1H-1,2,4-triazole;  
 1-((1E)-2-(5-(1H-1,2,4-triazol-3-yl)((1H-indazol-3-yl))vinyl)-4-methoxybenzene;  
 3-{3-((1E)-2-(4-chlorophenyl)vinyl)-1H-indazol-5-yl}-1H-1,2,4-triazole;  
 3-{3-((1E)-2-(4-methylphenyl)vinyl)-1H-indazol-5-yl}-1H-1,2,4-triazole;  
 4-({3-(3-(4-fluorophenyl)(1H-indazol-5-yl))-1H-1,2,4-triazol-5-yl}methyl)morpholine;  
 4-({5-(3-(4-fluorophenyl)-1H-indazol-5-yl)-1,3,4-oxadiazol-2-yl}methyl)morpholine;  
 1-({3-(3-(4-fluorophenyl)-1H-indazol-5-yl)-1H-1,2,4-triazol-5-yl}methyl)pyrrolidine-2-one;  
 3-(3-(4-fluorophenyl)(1H-indazol-5-yl))-5-(pyrrolidinylmethyl)-1H-1,2,4-triazole;  
 3-[3-((4-fluorophenyl)(1H-indazol-3-yl))]-5-[(4-pyrrolidinylpiperidyl)methyl]-1H-1,2,4-triazole;  
 5-(3-((1E)-2-phenylvinyl)-1H-indazole-5yl)-2H-1,2,3,4-tetrazole;  
 or a pharmaceutically acceptable salt thereof.